Details of the Drug

General Information of Drug (ID: DM3BH1Y)

Drug Name
Lapatinib
Synonyms
FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor)
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [1]
Gastroesophageal junction adenocarcinoma 2B71 Approved [2]
Melanoma 2C30 Approved [2]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EH01: Lapatinib
L01EH: Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 581.1
Logarithm of the Partition Coefficient (xlogp) 5.1
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 14.2 hours [4]
Metabolism
The drug is metabolized via the CYP3A4 and CYP3A5, with minor contributions from CYP2C19 and CYP2C8 to a variety of oxidated metabolites []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 30.73146 micromolar/kg/day [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.001 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Hepatotoxicty rs12153855 TNXB OTVBWAV5 [6]
Hepatotoxicty HLA-DQB1*02 HLA-DQB1 OTVVI3UI [6]
Hepatotoxicty HLA-DQA1*02 HLA-DQA1 OTC6GISG [6]
Chemical Identifiers
Formula
C29H26ClFN4O4S
IUPAC Name
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
Canonical SMILES
CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl
InChI
InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChIKey
BCFGMOOMADDAQU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
208908
ChEBI ID
CHEBI:49603
CAS Number
231277-92-2
UNII
0VUA21238F
DrugBank ID
DB01259
TTD ID
D08CDI
VARIDT ID
DR00120
INTEDE ID
DR0917
ACDINA ID
D00351
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [7]
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [7]
Eukaryotic elongation factor 2 kinase (eEF-2K) TT1QFLA EF2K_HUMAN Inhibitor [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [9]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5)
Main DME 		DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [11]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [13]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [14]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [14]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [15]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [17]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [17]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Gene/Protein Processing [17]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Gene/Protein Processing [18]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Gene/Protein Processing [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Breast cancer
ICD Disease Classification 2C60-2C65
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Epidermal growth factor receptor (EGFR) DTT EGFR 5.84E-05 0.32 0.55
P-glycoprotein 1 (ABCB1) DTP P-GP 1.42E-02 -2.10E-01 -5.11E-01
Breast cancer resistance protein (ABCG2) DTP BCRP 1.07E-06 -3.94E-01 -6.94E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 2.90E-11 -1.06E-01 -1.42E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 2.45E-13 -2.29E+00 -1.44E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.49E-08 -1.53E-01 -6.35E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.04E-04 -9.90E-02 -3.91E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 45 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC2 3.0846 4.5385 2.5061 5.8995
SK-N-MC CTRP2 2.4193 2.8557 2.4193 24.1507
NOS-1 [Human HNSCC] GDSC1; GDSC2 2.5136 4.2174 2.0997 10.1005
EW-7 GDSC2 2.7334 6.484 1.2271 15.0096
ES6 GDSC1; GDSC2 2.8588 5.6957 1.7299 11.1083
EW-1 GDSC1; GDSC2 2.9148 5.2669 1.9923 9.3463
ES8 GDSC1; GDSC2 2.9405 4.9993 2.1474 8.3268
ES7 GDSC1; GDSC2 3.0933 6.8766 1.3506 12.6599
HuO9 GDSC2 3.1126 4.7388 2.4323 6.2719
ES1 GDSC1; GDSC2 3.2195 4.8055 2.4931 5.3609
CHSA0108 GDSC2 3.3016 5.1776 2.3771 6.0413
CAL-72 GDSC2 3.3069 5.3657 2.2875 6.5926
EW-12 GDSC1; GDSC2 3.3643 5.0813 2.4773 5.0448
SK-PN-DW GDSC1; GDSC2 3.3985 4.8955 2.598 4.2148
SK-ES-1 GDSC1; GDSC2; CTRP2; CCLE 3.3986 5.014 3.3594 17.7588
MHH-ES-1 GDSC2; CTRP2; CCLE 3.5226 5.398 3.438 17.0893
EW-24 GDSC1; GDSC2 3.6117 6.2961 2.0689 6.8817
CHSA8926 GDSC2 3.7333 8.0824 1.2752 11.7065
EW-22 GDSC2 3.7823 8.5225 1.0947 12.6472
SaOS-2 GDSC2; CTRP2; CCLE 3.9279 6.2261 3.6826 14.9653
TC-71 GDSC1; GDSC2; CCLE 3.9866 6.1113 2.4348 3.2923
HuO-3N1 GDSC2 4.109 6.5239 2.3199 4.3874
A-673 GDSC2; CTRP2; CCLE 4.1251 4.9991 4.1188 12.8075
EW-3 GDSC1; GDSC2 4.2474 6.7315 2.313 4.0014
SJSA-1 GDSC1; GDSC2; CTRP2; CCLE 4.2712 6.0392 4.1107 12.3744
ES5 GDSC1; GDSC2 4.3171 8.2814 1.6147 7.9188
Hs 888.T CTRP2 4.3665 7.4539 3.7009 13.655
EW-11 GDSC1; GDSC2 4.3945 7.2803 2.1493 4.6548
EW-18 GDSC1; GDSC2 4.4324 6.4024 2.5791 2.2106
CHSA0011 GDSC2 4.4537 11.2323 0.2658 15.4609
U-CH2 GDSC2 4.5003 9.1895 1.3028 9.6225
CADO-ES1 GDSC2 4.5022 6.3872 2.6252 1.9393
H-EMC-SS GDSC1; GDSC2 4.7245 7.9484 2.047 4.6191
TC71 CTRP2 4.8074 8.3868 3.7312 12.405
EW-16 GDSC1; GDSC2 4.9911 14.2072 -0.8 18.6148
U2OS GDSC2; CCLE 5.0896 9.2498 1.6698 5.2351
NY GDSC2 5.6422 8.3481 2.3782 1.7476
EW-13 GDSC1; GDSC2 5.8562 7.5974 2.7566 0.3074
HOS GDSC2; CTRP2; CCLE 6.6308 10.3079 4.3794 5.9441
ES4 GDSC1; GDSC2 6.7795 20.3548 -2.5133 20.9426
CAL-78 GDSC2; CTRP2; CCLE 7.0806 10.406 4.6551 4.1165
MG-63 GDSC2; CTRP2; CCLE 7.152 14.3727 2.7634 11.6337
SW1353 CTRP2; CCLE 8.0654 12.9182 4.1103 4.9496
Hs 822.T CTRP2 8.1684 18.4791 1.4961 14.5871
G-292 clone A141B1 GDSC2; CTRP2 8.6261 12.8373 4.4817 2.9497
⏷ Show the Full List of 45 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 223 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 4.2448 6.1103 4.062 12.6307
JK1 CTRP2 4.3541 5.9416 4.2267 11.7041
JM1 GDSC1; GDSC2; CTRP2 3.8645 5.326 3.8161 14.6867
SUP-B8 GDSC2 0.9511 3.4922 0.6862 25.1801
KMS-21-BM CTRP2 1.1035 4.4132 0.9943 33.2748
Sc-1 GDSC1 1.6236 3.2105 0.3612 3.1767
KMS-34 CTRP2; CCLE 1.7389 3.3679 1.7344 28.6988
SU-DHL-5 GDSC2 1.8643 2.9721 1.8112 14.9006
MOLT-3 CTRP2 1.8737 2.9696 1.8734 27.7868
Karpas-45 GDSC1; GDSC2 1.9959 3.0375 1.9413 13.1189
GA-10 GDSC1; GDSC2; CTRP2 2.0382 3.0303 2.038 26.6905
LP-1 GDSC1; GDSC2; CTRP2; CCLE 2.0543 3.1006 2.0541 26.5832
ALL-PO GDSC1; GDSC2 2.0777 3.3554 1.9547 12.6813
Peer CTRP2 2.1198 4.2894 2.0834 26.2685
697 GDSC1; GDSC2; CTRP2; CCLE 2.1272 3.0171 2.1272 26.0968
EoL-1 GDSC1; GDSC2; CTRP2 2.1939 2.8145 2.1939 25.6529
LC4-1 GDSC1; GDSC2 2.1998 3.3868 2.079 11.4887
SUP-M2 GDSC1; GDSC2; CTRP2; CCLE 2.2183 3.2273 2.2181 25.4906
AMO1 GDSC1; GDSC2; CCLE 2.2304 3.0776 2.1874 9.3069
SU-DHL-6 GDSC1; GDSC2; CCLE 2.2337 2.9458 2.2119 9.1874
BC-3 GDSC1; GDSC2 2.2407 3.7262 2.0112 11.6807
U-698-M GDSC1; GDSC2 2.282 6.5176 0.7919 18.5036
RPMI-8402 GDSC1; GDSC2; CTRP2; CCLE 2.2924 3.9195 2.2831 25.0275
GR-ST GDSC1; GDSC2 2.3232 3.521 2.1718 10.4604
KMS-20 CTRP2 2.3305 3.8154 2.325 24.7607
BE-13 GDSC1; GDSC2 2.3577 3.3678 2.2567 9.8577
TALL-1 [Human adult T-ALL] GDSC2; CTRP2 2.3593 6.049 2.0215 25.7192
DG-75 GDSC1; GDSC2 2.4902 3.3875 2.3955 8.5434
NK-92MI GDSC1; GDSC2 2.504 3.303 2.4344 8.2771
NCO2 CCLE 2.516 7.8544 0.1586 16.4346
NALM-6 GDSC1; GDSC2; CTRP2 2.5321 3.7092 2.5306 23.4044
Ramos.2G6.4C10 GDSC1; GDSC2 2.5347 4.2007 2.1287 9.8537
WSU-NHL GDSC1; GDSC2 2.5365 3.316 2.4664 7.9655
KOPN-8 GDSC1; GDSC2 2.5837 3.6179 2.4197 8.0155
KMS-12-BM GDSC2; CTRP2; CCLE 2.5838 6.1019 2.2519 24.2101
ARH-77 GDSC1; GDSC2 2.5884 3.6948 2.3958 8.128
A4/Fukuda GDSC1; GDSC2; CTRP2 2.612 3.3358 2.612 22.867
P32/ISH GDSC1; GDSC2 2.6152 3.4326 2.5179 7.3489
CRO-AP2 GDSC2 2.6282 3.5354 2.4975 7.6692
Mino CTRP2; CCLE 2.6323 3.2032 2.6323 22.7321
MOLT-16 GDSC1; GDSC2; CTRP2; CCLE 2.6332 3.6361 2.6326 22.7279
BC-1 GDSC1; GDSC2 2.6449 3.8937 2.375 8.0203
AML-193 CTRP2 2.6512 3.0449 2.6512 22.6061
DoHH2 GDSC1; GDSC2; CCLE 2.6784 3.9807 2.3726 6.8188
DND-41 GDSC1; GDSC2 2.6819 4.0474 2.347 8.0393
JVM-2 GDSC1; GDSC2 2.7089 4.0724 2.3635 7.8425
DEL GDSC1; GDSC2; CTRP2; CCLE 2.7504 3.4976 2.7503 21.9454
Farage GDSC1; GDSC2 2.7555 4.1625 2.37 7.6321
Daudi GDSC1; GDSC2; CTRP2 2.7571 3.7577 2.7565 21.9025
ALL-SIL GDSC1; GDSC2; CCLE 2.7727 4.0716 2.4286 6.2341
KM-H2 GDSC1; GDSC2; CTRP2 2.7954 4.4365 2.7764 21.7091
H9 GDSC1; GDSC2 2.8065 3.9266 2.5277 6.5262
YT GDSC1; GDSC2 2.8119 3.6012 2.6703 5.6944
IM-9 GDSC1; GDSC2 2.8136 3.5775 2.6812 5.6269
CML-T1 GDSC2; CTRP2 2.8289 3.9094 2.8274 21.4271
PF-382 GDSC1; GDSC2; CTRP2 2.8414 5.2986 2.7206 21.7519
SU-DHL-16 GDSC1; GDSC2 2.8597 3.8929 2.597 5.9266
A3/Kawakami GDSC1; GDSC2; CTRP2 2.8872 3.6697 2.8871 21.034
KMS-11 GDSC2; CTRP2; CCLE 2.901 4.6439 2.8714 21.0412
P12-Ichikawa GDSC2; CTRP2; CCLE 2.9063 4.1025 2.9029 20.9176
CA46 GDSC1; GDSC2; CTRP2 2.9136 5.4811 2.7633 21.3742
MLMA GDSC1; GDSC2 2.9183 3.9638 2.624 5.5529
Ki-JK CTRP2 2.9579 4.0461 2.956 20.5691
K-562 GDSC1; GDSC2; CTRP2 2.9622 4.017 2.9607 20.5389
SEM CTRP2 2.9765 3.7842 2.9763 20.4392
CCRF-CEM GDSC1; GDSC2 2.9811 4.806 2.2797 7.3965
Karpas-1106P GDSC2 2.9886 5.7564 1.8168 10.5392
HT GDSC1; GDSC2; CTRP2; CCLE 3.03 9.8874 1.2634 26.3484
Reh GDSC1; GDSC2; CTRP2; CCLE 3.0424 4.7652 3.009 20.1121
JVM-3 GDSC1; GDSC2; CTRP2; CCLE 3.0511 5.321 2.943 20.311
SU-DHL-1 GDSC1; GDSC2; CTRP2 3.07 8.9854 1.7014 24.7442
KE-37 GDSC1; GDSC2; CTRP2 3.0946 4.2136 3.0915 19.6624
MOLT-13 GDSC2; CTRP2 3.1114 5.7621 2.916 20.2167
SU-DHL-4 GDSC1; GDSC2; CTRP2; CCLE 3.1142 4.8088 3.0804 19.6355
ML-2 GDSC1; GDSC2 3.123 4.34 2.6389 4.7693
ST486 GDSC1; GDSC2; CTRP2 3.1421 4.6149 3.1246 19.3941
OCI-Ly7 GDSC2 3.1454 4.2397 2.7087 4.4282
KMS-26 CTRP2; CCLE 3.1469 4.3676 3.1409 19.3237
ATN-1 GDSC1; GDSC2 3.157 4.7199 2.4812 5.6217
Pfeiffer CTRP2; CCLE 3.1678 4.6446 3.1495 19.2255
BL-70 CTRP2; CCLE 3.1701 4.4677 3.1611 19.1793
WSU-DLCL2 GDSC1; GDSC2; CTRP2 3.1732 4.188 3.1713 19.1347
Kasumi-2 CTRP2; CCLE 3.1733 3.9322 3.1731 19.1282
M-07e CTRP2 3.1854 4.1854 3.1837 19.0528
RPMI-8226 GDSC1; GDSC2; CTRP2 3.1895 4.5259 3.1784 19.0568
NU-DUL-1 GDSC1; GDSC2; CTRP2 3.1916 4.8388 3.159 19.1155
MV4-11 GDSC1; GDSC2; CTRP2 3.1927 4.7966 3.1639 19.0951
VAL GDSC1; GDSC2 3.231 5.1005 2.3558 6.1655
NB4 GDSC1; GDSC2; CTRP2 3.2438 6.9208 2.7106 20.5674
RC-K8 GDSC1; GDSC2 3.2462 4.4124 2.7124 3.9441
SUP-T11 CTRP2 3.2486 14.4527 -0.6686 31.1581
CTB-1 GDSC1; GDSC2 3.2665 5.3907 2.241 6.7644
F-36P CTRP2; CCLE 3.2666 4.6949 3.2487 18.5659
L-428 GDSC1; GDSC2; CTRP2; CCLE 3.2787 4.6212 3.2656 18.4693
HDLM-2 GDSC1; GDSC2; CTRP2 3.3018 6.8756 2.7893 20.107
SCC-3 GDSC1; GDSC2 3.3057 5.7956 2.0716 7.6871
MN-60 GDSC1; GDSC2 3.3148 4.7688 2.5926 4.4783
Mono-Mac-1 CTRP2; CCLE 3.3192 5.4191 3.2148 18.5129
Ku812 GDSC1; GDSC2; CTRP2; CCLE 3.3282 5.287 3.2473 18.3713
OPM-2 GDSC1; GDSC2; CTRP2; CCLE 3.3339 4.518 3.3269 18.0814
Loucy GDSC1; GDSC2 3.3588 4.6207 2.703 3.6809
Jurkat GDSC2; CTRP2; CCLE 3.3649 5.0491 3.3198 18.0038
HAL-01 GDSC1; GDSC2 3.3688 4.8651 2.5891 4.3498
U-937 CTRP2; CCLE 3.3988 6.2982 3.0841 18.7354
Jiyoye GDSC1; GDSC2 3.4185 4.8561 2.6338 3.943
NU-DHL-1 CTRP2 3.4227 4.4535 3.4192 17.4776
EB2 GDSC1; GDSC2; CCLE 3.4242 5.9856 2.0743 6.3347
Ri-1 CTRP2 3.425 5.3871 3.3347 17.759
RPMI-8866 GDSC1; GDSC2 3.4503 4.7554 2.7092 3.4002
SUP-T1 GDSC1; GDSC2; CTRP2; CCLE 3.4607 4.9193 3.4341 17.3024
MOLM-13 GDSC1; GDSC2; CTRP2 3.4684 5.3833 3.3822 17.4559
WIL2 NS GDSC1; GDSC2 3.4708 5.2401 2.4839 4.7197
JJN-3 GDSC1; GDSC2; CTRP2 3.489 4.9399 3.462 17.1154
KMS-18 CTRP2 3.494 7.0611 2.9296 19.0287
OCI-AML-2 GDSC1; GDSC2; CTRP2; CCLE 3.5222 4.4116 3.5206 16.8087
RCH-ACV GDSC2; CTRP2 3.5224 5.4005 3.4374 17.092
KMOE-2 GDSC1; GDSC2 3.5314 5.4814 2.4114 5.0049
MOTN-1 CTRP2 3.5425 5.5329 3.4347 17.0377
Ci-1 CCLE 3.5621 4.7821 2.5224 1.4783
Mono-Mac-6 GDSC1; GDSC2 3.5697 6.1408 2.1133 6.7196
MHH-PREB-1 GDSC1; GDSC2 3.5845 6.6151 1.8887 8.0446
KY821 GDSC1; GDSC2 3.6005 5.3201 2.5445 4.0254
GDM-1 GDSC1; GDSC2; CTRP2 3.602 4.9809 3.5769 16.3557
Karpas-299 GDSC1; GDSC2; CTRP2; CCLE 3.603 4.3594 3.6024 16.2667
DB GDSC1; GDSC2; CTRP2 3.6176 5.4799 3.526 16.4811
MOLT-4 GDSC1; GDSC2 3.6259 6.9224 1.7683 8.6651
RS4;11 GDSC1; GDSC2 3.6371 6.2181 2.1273 6.4627
HEL GDSC1; GDSC2; CTRP2 3.653 5.2658 3.5986 16.1162
MOLM-16 GDSC2; CTRP2 3.6664 6.9394 3.1596 17.6714
RL GDSC1; GDSC2; CTRP2 3.6877 8.2504 2.6567 19.5256
Raji GDSC1; GDSC2; CTRP2; CCLE 3.7107 5.6384 3.5958 15.9425
TUR GDSC1; GDSC2 3.7255 5.6282 2.4854 4.0855
NOMO-1 GDSC1; GDSC2 3.7408 5.7209 2.4511 4.2566
KHM-1B CTRP2; CCLE 3.7606 6.8533 3.2923 16.9029
EB1 CTRP2; CCLE 3.7688 5.6615 3.6541 15.5553
OCI-AML-3 GDSC1; GDSC2 3.7789 5.732 2.4733 4.0367
HC-1 GDSC1; GDSC2 3.7859 6.7218 1.9915 6.9151
BALL-1 GDSC1; GDSC2 3.7908 5.8964 2.4015 4.4389
MEC-1 CCLE 3.8503 6.2968 1.995 3.6579
NKM-1 GDSC1; GDSC2 3.8515 6.308 2.2439 5.2428
CMK-86 CCLE 3.8769 6.0927 2.1091 3.0316
JURL-MK1 GDSC1; GDSC2; CTRP2 3.9172 5.2878 3.8773 14.3069
MEG-01 GDSC1; GDSC2; CCLE 3.9202 5.901 2.4905 3.1297
MY-M12 GDSC1; GDSC2 3.9522 7.1225 1.9179 6.9599
HH [Human lymphoma] GDSC1; GDSC2; CTRP2; CCLE 3.9587 5.5429 3.8829 14.1546
HuT 78 CTRP2; CCLE 3.9898 5.682 3.8896 14.0326
CESS GDSC1; GDSC2 3.9978 6.0708 2.4618 3.6358
EM-2 GDSC1; GDSC2; CTRP2; CCLE 4.0263 5.1154 4.0096 13.5009
BV-173 GDSC1; GDSC2; CTRP2 4.0364 7.4463 3.3579 15.8806
JSC-1 GDSC1; GDSC2 4.0375 6.3886 2.3362 4.2881
PL21 CTRP2 4.0497 9.5868 2.4239 19.4676
ROS-50 GDSC1; GDSC2 4.0758 6.0015 2.5462 2.9959
P30/OHK GDSC1; GDSC2 4.0825 7.6602 1.7494 7.6589
KG-1 GDSC1; GDSC2; CCLE 4.1308 5.9187 2.6197 2.1414
VL51 GDSC1; GDSC2 4.1682 6.3023 2.4642 3.2886
EJM GDSC1; GDSC2; CTRP2 4.1994 7.0299 3.6965 14.1291
MM1.S GDSC2; CTRP2 4.2186 7.1228 3.6805 14.1368
CTV-1 GDSC1; GDSC2 4.229 6.4026 2.456 3.2227
REC-1 CTRP2 4.2351 10.6119 2.1205 20.1499
SUP-HD1 GDSC1; GDSC2; CTRP2 4.2637 7.3709 3.6278 14.217
PL-21 GDSC1; GDSC2 4.2674 6.9501 2.2224 4.4834
P31/FUJ GDSC1; GDSC2; CTRP2; CCLE 4.2922 7.2981 3.6877 13.9072
OCI-Ly3 CTRP2 4.2991 7.7981 3.4839 14.684
THP-1 GDSC1; GDSC2; CTRP2 4.304 5.4068 4.2737 11.6972
MC116 GDSC1; GDSC2; CTRP2; CCLE 4.3162 6.8956 3.8729 13.1286
ME1 GDSC1; GDSC2 4.3184 6.0445 2.6741 1.8861
MJ CCLE 4.3541 7.2902 1.8509 3.5533
MOLP-8 GDSC1; GDSC2; CTRP2; CCLE 4.3756 8.6786 3.1676 15.7381
BONNA-12 GDSC2 4.3956 9.0514 1.2952 9.9111
L-363 GDSC1; GDSC2; CTRP2; CCLE 4.4044 5.7143 4.3327 11.172
SR GDSC1; GDSC2; CTRP2 4.4389 8.4735 3.325 14.9527
Namalwa GDSC1; GDSC2; CTRP2 4.4814 7.3567 3.8616 12.7196
L-540 GDSC1; GDSC2; CTRP2 4.4998 9.3273 2.9877 16.1454
JeKo-1 GDSC2; CTRP2 4.5092 9.0716 3.1173 15.606
SET-2 CTRP2 4.5516 4.9961 4.5513 9.9462
KO52 CCLE 4.5809 6.3575 2.3842 0.9193
LAMA-84 GDSC1; GDSC2; CTRP2 4.6223 8.5484 3.4732 13.9009
HD-MY-Z CTRP2; CCLE 4.6774 7.0821 4.1813 10.9453
KMS-27 CTRP2 4.6897 7.0744 4.1973 10.8499
QIMR-WIL GDSC1; GDSC2 4.7535 7.3934 2.3193 3.0867
SK-MM-2 GDSC1; GDSC2; CCLE 4.7656 7.2155 2.4059 2.2564
SU-DHL-10 GDSC2; CTRP2; CCLE 4.8004 6.5329 4.5278 9.2739
U266B1 GDSC1; GDSC2; CTRP2 4.8718 7.3831 4.254 10.1445
MHH-CALL-2 GDSC2 4.9131 6.3568 2.8379 0.5609
HPB-ALL CTRP2 4.9434 8.7726 3.6811 12.2814
Karpas-231 GDSC1; GDSC2 4.9595 6.3136 2.8735 0.4048
TK [Human B-cell lymphoma] GDSC1; GDSC2 5.0122 6.5104 2.8213 0.5318
KCL-22 GDSC1; GDSC2; CTRP2; CCLE 5.0175 8.5844 3.8423 11.4474
Kasumi-1 GDSC1; GDSC2; CTRP2 5.1601 10.628 2.9796 14.6408
Toledo CCLE 5.3382 7.6176 2.2279 0.8894
JM-1 CCLE 5.4073 6.9489 2.5024 0.1918
Hs 445 GDSC1; GDSC2 5.4295 6.7014 2.9131 0.1452
BDCM CCLE 5.5066 7.288 2.4198 0.3094
RPMI-6666 GDSC1; GDSC2; CTRP2 5.5176 10.0102 3.6071 11.2978
SUP-B15 GDSC1; GDSC2; CTRP2 5.645 8.7272 4.3572 7.9022
MOLM-6 CTRP2 5.6665 13.4288 2.0327 17.2353
L-1236 GDSC1; GDSC2; CTRP2 5.7715 12.3516 2.6606 14.6141
EHEB GDSC1; CTRP2 6.0643 12.2136 2.9764 12.771
SIG-M5 GDSC1; GDSC2; CTRP2; CCLE 6.0778 6.9606 5.6138 1.7466
OCI-M1 GDSC1; GDSC2; CTRP2 6.1112 8.9264 4.6587 5.6969
HL-60 GDSC1; GDSC2; CTRP2 6.1151 7.9913 5.1292 3.7128
SU-DHL-8 GDSC1; GDSC2; CTRP2; CCLE 6.1187 7.6513 5.302 2.9801
OCI-Ly19 GDSC1; GDSC2; CTRP2 6.1725 9.536 4.4042 6.6504
OCI-Ly10 CTRP2; CCLE 6.3 11.2477 3.6526 9.5539
TF-1 CTRP2 6.3023 10.1977 4.1786 7.3568
P3HR-1 CTRP2; CCLE 6.3575 8.4983 5.0676 3.5398
Granta-519 GDSC1; GDSC2; CTRP2; CCLE 6.4391 9.567 4.6002 5.3497
MHH-CALL-3 CTRP2 6.4753 8.4375 5.1852 2.86
Hs 611.T CTRP2 6.6476 12.9142 3.0983 11.1875
KYO-1 CTRP2 6.7345 18.6598 0.3022 20.8869
CMK CTRP2 6.7585 11.725 3.775 8.2321
NCI-H929 GDSC2; CTRP2 6.782 10.3513 4.4705 5.3203
KE-97 CTRP2; CCLE 7.1484 15.7793 2.0636 14.2904
HEL 92.1.7 CTRP2; CCLE 7.175 9.9532 4.9327 2.888
MOLP-2 CTRP2 7.645 10.0689 5.1575 1.5474
Karpas-422 GDSC1; GDSC2; CTRP2; CCLE 7.6895 12.0271 4.2879 4.7433
Karpas-620 GDSC2; CTRP2; CCLE 7.7788 9.262 5.5511 0.3319
OCI-AML-5 GDSC1; GDSC2; CTRP2; CCLE 7.9105 9.3017 5.5891 0.2158
BL-41 GDSC1; GDSC2; CTRP2; CCLE 7.956 9.2206 5.6352 0.136
MHH-CALL-4 GDSC2; CTRP2 8.1499 10.0507 5.4076 0.4845
ME1 CTRP2 8.9656 17.5376 2.5122 9.8043
KMM-1 CTRP2; CCLE 8.9712 11.3218 5.2687 0.4478
SKM-1 GDSC1; GDSC2; CTRP2 9.3693 17.2807 2.8965 7.8754
⏷ Show the Full List of 223 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 -0.052 7.8982 -1.1936 42.747
TE8 CTRP2 3.9834 12.7183 0.8654 25.1032
TE-4 GDSC2; CTRP2 -0.0969 4.4286 -0.2958 41.4089
OE21 GDSC2; CTRP2; CCLE 0.5329 4.1303 0.4236 37.0558
TE-15 GDSC1; GDSC2; CCLE 0.651 6.411 -0.7738 28.4513
OE19 GDSC2; CTRP2 1.2686 6.3811 0.7367 33.5006
TE-14 CTRP2 1.4046 8.0845 0.3071 34.2372
KYSE-140 GDSC2; CTRP2; CCLE 1.4846 6.0874 1.0563 31.7828
TE-6 GDSC1; GDSC2; CTRP2 1.5217 6.6165 0.9413 32.0182
T.T GDSC2 1.6466 5.6203 0.5917 22.682
TE-11 GDSC2; CTRP2; CCLE 1.7767 8.6146 0.4993 32.4742
KYSE-410 GDSC2; CTRP2; CCLE 2.1743 6.8692 1.5699 27.8612
EC-GI-10 GDSC1; GDSC2; CTRP2 2.3985 9.3764 0.8381 29.5369
KYSE-520 GDSC2; CTRP2; CCLE 2.5456 7.7067 1.6713 26.3755
OE33 GDSC2; CTRP2; CCLE 2.6767 7.323 1.955 24.9872
KYSE-270 GDSC2 3.1082 9.5025 0.0518 20.3282
TE-5 GDSC1; GDSC2; CTRP2; CCLE 3.3317 9.6571 1.6726 24.1188
TE-1 GDSC1; GDSC2; CTRP2; CCLE 3.9632 11.0274 1.6602 22.5013
KYSE-70 GDSC2; CTRP2; CCLE 4.03 8.9206 2.7105 18.4144
KYSE-180 GDSC2; CTRP2; CCLE 5.2588 12.6589 2.0617 17.9952
TE-8 GDSC1; GDSC2 5.5004 14.5053 -0.5746 16.5177
KYSE-450 GDSC2; CTRP2; CCLE 5.6968 12.7299 2.4078 15.7529
TE-10 GDSC1; GDSC2; CTRP2 5.7178 12.1416 2.7196 14.491
TE-9 GDSC1; GDSC2; CTRP2; CCLE 6.6652 14.2866 2.4286 13.7884
COLO 680N GDSC2; CTRP2 8.025 17.5508 1.8467 13.6017
KYSE-510 GDSC2; CTRP2; CCLE 8.5608 16.1403 2.9083 8.901
KYSE-150 GDSC2; CTRP2; CCLE 8.774 16.3418 2.9542 8.4363
KYSE-30 CTRP2; CCLE 8.878 21.6225 0.4721 16.7446
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 43 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 4.779 11.276 2.3114 18.1296
KCI-MOH1 CCLE 2.3429 4.9331 1.443 10.2268
HuP-T4 GDSC2; CTRP2; CCLE 2.5842 4.4218 2.5579 23.1406
PK-1 CCLE 2.8456 5.2825 1.7277 7.2878
Panc 10.05 GDSC2; CTRP2; CCLE 3.0511 6.3121 2.7009 21.1738
KP-1N GDSC2; CCLE 3.48 6.2882 1.9684 6.7628
KP-1NL CCLE 3.6873 6.7688 1.6532 5.7532
PL45 CCLE 3.7083 6.5351 1.7823 5.0299
Panc 03.27 GDSC2; CTRP2; CCLE 3.7731 8.3857 2.6866 19.1817
HPAC GDSC2; CCLE 4.1191 7.3972 1.9044 5.7485
PL4 GDSC2 4.2317 6.4228 2.4483 3.3662
QGP-1 GDSC2; CTRP2; CCLE 4.34 11.0991 1.9864 20.3902
Panc 05.04 CTRP2 4.3695 14.0868 0.5544 25.1163
Panc 08.13 GDSC2; CTRP2 4.4073 12.1191 1.5541 21.7793
MIA PaCa-2 GDSC2; CTRP2; CCLE 4.4249 6.9939 3.9504 12.5293
BxPC-3 GDSC2; CTRP2; CCLE 4.6217 11.4052 2.1024 19.2862
SU.86.86 GDSC2; CTRP2; CCLE 4.9278 8.3163 3.8824 11.499
PaTu 8902 GDSC2; CTRP2; CCLE 5.2263 8.2473 4.2042 9.4736
Hs 766T GDSC2; CTRP2; CCLE 5.2427 10.2906 3.2211 13.4798
MZ-PC-1 GDSC1; GDSC2 5.2627 10.7489 1.0746 8.9715
YAPC GDSC2; CTRP2 5.5311 9.0338 4.103 9.2073
PaTu 8988s CTRP2 5.5633 9.1687 4.0651 9.2958
TCC-Pan2 CTRP2 5.6603 10.0184 3.7289 10.4921
PK-59 CTRP2; CCLE 5.7547 10.9139 3.3642 11.808
Capan-1 GDSC2; CTRP2 5.8159 10.7858 3.4807 11.2035
L3.3 CTRP2; CCLE 5.8582 13.4812 2.1697 16.3297
DAN-G GDSC2; CTRP2 6.0422 11.5649 3.2823 11.5716
SW1990 GDSC2; CTRP2; CCLE 6.5098 14.0452 2.4249 14.0902
KP-4 GDSC2; CTRP2; CCLE 6.758 9.9617 4.644 4.6437
PK-45H CTRP2; CCLE 6.9488 13.0134 3.2819 9.9214
HPAF-II GDSC2; CTRP2; CCLE 6.9513 12.8188 3.3801 9.5201
SNU-213 CTRP2 7.0281 15.851 1.9348 14.9727
PSN1 GDSC1; GDSC2; CTRP2; CCLE 7.0933 12.3476 3.7185 7.9098
CFPAC-1 GDSC2; CTRP2 7.3359 14.4577 2.8596 10.9506
KP-3 GDSC2; CTRP2; CCLE 7.4449 13.118 3.5959 7.853
HuP-T3 GDSC2; CTRP2; CCLE 7.5226 12.4441 3.977 6.2077
AsPC-1 GDSC2; CTRP2; CCLE 7.7662 16.7566 2.0467 13.3057
SUIT-2 GDSC2; CTRP2; CCLE 8.0926 12.8518 4.1586 4.7302
PaTu 8988t GDSC2; CTRP2 8.1353 12.1366 4.514 3.3417
Capan-2 GDSC2; CTRP2; CCLE 8.5791 17.3174 2.355 10.9252
KP-2 GDSC2; CTRP2; CCLE 8.7265 13.8466 4.087 4.2588
Panc 02.03 GDSC2; CTRP2; CCLE 8.9866 14.8435 3.7878 5.0647
Panc 04.03 GDSC2; CTRP2; CCLE 9.4075 17.161 2.9764 7.538
⏷ Show the Full List of 43 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 78 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 3.7811 13.4141 0.3373 27.1939
A-388 GDSC1; GDSC2 0.0696 4.3049 -0.5373 34.2081
CHL-1 GDSC2; CCLE 0.8643 5.2346 -0.0472 24.641
A-431 GDSC2 0.9628 4.6463 0.2947 27.1792
G-mel GDSC2 2.1704 3.3358 2.0614 12.131
G-361 GDSC2; CCLE 2.1753 3.1774 2.1069 9.8792
MZ-MEL-7 GDSC1; GDSC2 2.2373 3.3506 2.1303 11.054
HMV-II GDSC2 2.738 4.9605 1.9765 10.3823
Malme-3M CCLE 2.8293 4.9458 1.8814 6.4999
Mel Ho GDSC2; CTRP2; CCLE 2.8787 4.0199 2.8763 21.0984
SK-MEL-24 GDSC2; CTRP2; CCLE 3.0385 4.1414 3.036 20.0339
HT-144 GDSC1; GDSC2; CTRP2; CCLE 3.0453 4.5533 3.0281 20.0381
MZ-MEL-2 GDSC1; GDSC2 3.1123 6.9111 1.3498 12.6081
M14 GDSC2 3.1236 4.96 2.3323 6.867
DJM-1 GDSC1; GDSC2 3.3155 7.6533 1.1509 13.1857
COLO 783 GDSC2 3.3949 5.0064 2.5397 4.7449
IGR-1 GDSC2; CTRP2 3.4017 11.7591 0.7683 26.9044
CP50-MEL-B GDSC2 3.7048 8.5415 1.024 13.2738
Hs 940.T GDSC2 3.8073 5.8849 2.419 4.4507
VMRC-MELG GDSC2 3.8514 8.1208 1.3483 10.9513
COLO 741 CCLE 3.874 6.9858 1.6801 5.2459
Hs 938.T GDSC2; CCLE 3.8919 5.53 2.6492 2.3814
WM278 GDSC2 3.9148 6.6187 2.1377 5.9377
WM1552C GDSC2 3.9242 6.6371 2.1355 5.929
COLO 792 GDSC2; CTRP2 3.928 4.85 3.9226 14.118
SH-4 GDSC1; GDSC2 4.0373 6.4022 2.3295 4.3276
RPMI-7951 GDSC2; CTRP2; CCLE 4.04 5.3287 4.0027 13.4798
GAK GDSC2 4.0942 11.3483 -0.0672 18.0577
IST-MEL1 GDSC1; GDSC2 4.0995 8.5247 1.3367 10.0404
LB373-MEL-D GDSC1; GDSC2 4.1988 8.1677 1.5853 8.3576
Hs 944.T CTRP2; CCLE 4.3473 6.1809 4.1534 11.9896
IPC-298 GDSC2; CTRP2; CCLE 4.3739 5.7102 4.3005 11.3809
UACC-257 GDSC1; GDSC2; CCLE 4.3954 6.4697 2.5271 2.195
Mel JuSo GDSC2; CTRP2 4.5003 5.5974 4.4569 10.4349
LOX-IMVI GDSC1; GDSC2; CTRP2; CCLE 4.5075 6.4825 4.23 11.2344
WM35 GDSC2 4.5231 7.0369 2.3444 3.4446
HMCB CTRP2; CCLE 4.5294 7.3046 3.9337 12.3091
IGR-37 GDSC2; CTRP2; CCLE 4.5481 7.1134 4.0325 11.8741
WM115 GDSC2; CTRP2; CCLE 4.5508 5.642 4.5039 10.1104
MeWo GDSC2; CTRP2; CCLE 4.5896 6.967 4.1356 11.3617
WM793 GDSC2; CTRP2; CCLE 4.668 10.0819 2.7888 16.5304
Hs 936.T CTRP2; CCLE 4.6775 5.9674 4.573 9.4702
451Lu GDSC2 4.7347 8.937 1.5865 7.4453
COLO 800 GDSC1; GDSC2; CTRP2 4.8686 7.9708 3.9851 11.2289
MDA-MB-435S CTRP2; CCLE 4.9611 8.5844 3.788 11.8031
CP66-MEL GDSC1; GDSC2 4.9623 6.2127 2.9117 0.3005
A-375 GDSC2; CTRP2; CCLE 4.9667 9.5723 3.3178 13.7079
Hs 695T CCLE 5.0077 8.8157 1.546 4.0586
LB2518-MEL GDSC1; GDSC2 5.1655 6.6185 2.8435 0.3827
SF8657 CCLE 5.1848 7.0321 2.3865 0.518
MMAc-SF GDSC1; GDSC2 5.2742 8.8284 1.9752 4.0931
SK-MEL-3 GDSC2; CTRP2 5.3442 9.0949 3.9024 10.4504
Hs 294T CTRP2; CCLE 5.4317 9.7282 3.6699 11.2215
CJM [Human melanoma] CTRP2 5.4611 15.5342 0.805 21.8897
COLO 679 GDSC2; CCLE 5.4926 7.1687 2.7713 0.3601
WM1799 CTRP2; CCLE 6.7326 12.5763 3.3328 10.0886
WM983B CTRP2; CCLE 6.747 12.7436 3.2608 10.3555
WM266-4 CTRP2; CCLE 6.7552 8.8653 5.1734 2.4952
SK-MEL-5 GDSC2; CTRP2; CCLE 6.9087 10.2405 4.6157 4.5279
WM88 CTRP2; CCLE 6.9764 8.7355 5.3733 1.4493
Hs 895.T CTRP2; CCLE 7.1843 11.0041 4.4382 4.8416
SK-MEL-28 GDSC2; CTRP2 7.2337 8.3785 5.6573 0.3371
Hs 688(A).T CTRP2 7.3305 11.22 4.434 4.6509
SK-MEL-2 GDSC1; GDSC2; CTRP2; CCLE 7.4232 8.5621 5.6673 0.2334
WT2-iPS GDSC2; CTRP2; CCLE 7.4494 9.0762 5.4777 0.6889
IGR-39 CTRP2; CCLE 7.4547 11.4129 4.425 4.5164
RVH-421 GDSC2; CTRP2; CCLE 7.4801 10.9343 4.6673 3.5329
UACC-62 GDSC2; CTRP2; CCLE 7.5187 9.353 5.3972 0.878
SK-MEL-1 GDSC1; GDSC2; CTRP2 7.5416 10.3365 4.9804 2.2767
Hs 852.T CTRP2; CCLE 7.57 10.2698 5.0269 2.0775
Hs 839.T CTRP2 7.6226 8.7644 5.6719 0.1622
A101D GDSC1; GDSC2; CTRP2 7.6739 9.2818 5.4987 0.4995
COLO 829 GDSC1; GDSC2; CTRP2 7.809 11.5663 4.5788 3.4713
K029AX CTRP2; CCLE 8.0274 10.7369 5.072 1.4997
SK-MEL-30 GDSC2; CTRP2; CCLE 8.0285 9.1899 5.6719 0.0816
A2058 GDSC2; CTRP2; CCLE 8.0427 9.9346 5.4063 0.5374
SK-MEL-31 GDSC2; CTRP2; CCLE 8.1269 9.4606 5.6139 0.1288
EquiPSC Line K2 GDSC2 5.4491 9.6046 1.7264 5.3056
⏷ Show the Full List of 78 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYAE-1 GDSC2 -0.3114 2.8196 -0.5183 37.3694
TE-12 GDSC1; GDSC2 -0.0816 6.9881 -1.7783 38.83
KYSE-220 GDSC2 1.6755 5.1343 0.8376 21.1991
OACP4 C GDSC2 1.8633 4.7143 1.2137 18.2822
ESO-26 GDSC2 1.9916 8.0332 -0.2171 25.4318
OACM5.1 C GDSC2 1.9986 8.3797 -0.3797 26.1403
KYSE-50 GDSC2 2.9548 5.3149 2.0051 9.4689
ESO-51 GDSC2 3.6668 5.4096 2.5497 3.9736
FLO-1 GDSC2 3.7625 8.6205 1.0303 13.0786
HCE-4 GDSC2 4.4966 9.1267 1.3307 9.4682
SK-GT-4 GDSC2 5.0564 15.8382 -1.556 21.8533
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2; CTRP2 3.5269 5.7122 3.38 17.2794
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KP-N-RT-BM-1 GDSC2 1.2491 2.7639 1.1841 21.1346
NB(TU)1 GDSC1; GDSC2 2.3505 3.2389 2.2833 9.7501
CHP-134 GDSC2 2.5388 3.2656 2.4819 8.1566
SJNB-13 GDSC1; GDSC2 2.5539 3.4383 2.4493 7.9806
KP-N-YS GDSC1; GDSC2 2.6571 4.2148 2.2471 8.7098
NB69 GDSC1; GDSC2 2.7604 4.8794 2.037 9.586
Kelly GDSC1; GDSC2; CTRP2; CCLE 2.8523 3.5295 2.8523 21.2662
SJNB-14 GDSC1; GDSC2 2.9496 4.2141 2.5373 5.9548
GOTO GDSC1; GDSC2 2.9607 4.1255 2.5902 5.6018
SK-N-DZ GDSC1; GDSC2; CCLE 3.1637 4.6865 2.5036 4.7138
SJNB-17 GDSC1; GDSC2 3.1689 4.8808 2.4116 6.0093
SK-N-BE(2)-M17 GDSC1; GDSC2 3.1727 4.6321 2.5386 5.224
NH-12 GDSC1; GDSC2 3.213 4.5179 2.6309 4.5398
SK-N-SH GDSC2; CCLE 3.2481 4.5775 2.6316 3.8228
IMR-5 GDSC1; GDSC2 3.2685 4.5256 2.675 4.1066
SJNB-12 GDSC1; GDSC2 3.2765 5.6705 2.1096 7.538
IMR-32 CCLE 3.3016 6.0233 1.7317 6.1568
SK-N-MC-IXC GDSC2 3.311 4.8402 2.5537 4.8958
SK-N-BE(2) CTRP2; CCLE 3.4039 4.4002 3.4012 17.6003
SJNB-6 GDSC1; GDSC2 3.4396 5.0024 2.5776 4.23
SiMa GDSC1; GDSC2; CCLE 3.5501 5.2961 2.518 3.7178
LA-N-6 GDSC1; GDSC2 3.7903 6.419 2.1443 5.9847
KP-N-YN GDSC1; GDSC2 4.0062 7.4848 1.7796 7.6576
CHP-212 GDSC2; CTRP2; CCLE 4.0806 6.8108 3.6521 14.6328
SK-N-AS GDSC2; CTRP2; CCLE 4.2511 5.6537 4.1784 12.1962
TGW GDSC1; GDSC2 4.4136 6.2714 2.6269 1.9898
SJNB-7 GDSC1; GDSC2 4.4207 7.94 1.852 6.3164
SJNB-10 GDSC1; GDSC2 4.6174 6.9798 2.4265 2.7305
KP-N-SI9s CTRP2; CCLE 4.6959 6.9525 4.2538 10.614
MHH-NB-11 GDSC1; GDSC2 4.8203 8.8435 1.6878 6.455
NB1 GDSC1; GDSC2; CTRP2 4.8248 6.9224 4.4018 9.689
SJNB-5 GDSC1; GDSC2 4.9213 11.5066 0.4738 12.8618
SK-N-FI GDSC1; GDSC2; CCLE 5.4537 6.9985 2.8178 0.2767
GI-ME-N GDSC1; GDSC2 5.862 10.8695 1.3961 6.1863
CHP-126 GDSC1; GDSC2; CTRP2 6.587 8.7667 5.1047 3.0176
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-1079 CTRP2 -0.6409 4.9191 -0.9779 45.0818
SNU-478 CTRP2 0.4391 6.8309 -0.3044 39.2282
SNU-308 CTRP2 2.8643 9.2164 1.3891 26.4015
HuCC-T1 GDSC2; CTRP2; CCLE 3.664 8.806 2.3904 20.6005
HuH-28 CTRP2 5.5638 8.9316 4.1831 8.8028
SNU-869 CTRP2 6.0466 10.1014 4.0177 8.5109
SNU-1196 CTRP2 9.8714 22.3064 0.8395 14.1735
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC2218 GDSC1; GDSC2; CTRP2 -3.1358 2.6319 -3.2901 59.8798
MDA-MB-175-VII GDSC2; CCLE -1.8327 1.5577 -1.9383 43.3716
AU565 GDSC2; CCLE -1.6788 3.9948 -2.3331 43.2914
ZR-75-30 GDSC2; CTRP2; CCLE -1.434 6.798 -2.3346 49.8645
SK-BR-3 CCLE -1.3375 4.8015 -2.3241 40.1657
UACC-893 GDSC2 -0.9524 2.1127 -1.0769 43.1512
MDA-MB-330 GDSC2 0.1403 9.0739 -2.5003 40.1586
BT-474 GDSC1; GDSC2; CTRP2; CCLE 0.4955 7.0629 -0.3171 39.0348
HCC2157 GDSC1; GDSC2 0.9085 5.5995 -0.1552 28.6661
EFM-192A GDSC2 0.9296 9.6438 -2.0017 35.7939
OCUB-M GDSC1; GDSC2 1.0923 8.9435 -1.5102 33.033
HCC1954 GDSC2; CTRP2; CCLE 1.2611 4.6936 1.1214 32.3278
MDA-MB-468 GDSC2; CTRP2; CCLE 1.7766 4.4579 1.7049 28.6737
DU4475 GDSC1; GDSC2; CTRP2 1.994 2.709 1.994 26.9841
MDA-MB-453 GDSC2; CTRP2; CCLE 2.1092 7.9599 1.1084 29.5872
HCC202 CTRP2 2.1652 9.5307 0.53 31.1557
CAL-85-1 GDSC2; CTRP2; CCLE 2.1824 6.4429 1.7144 27.3408
UACC-812 GDSC1; GDSC2; CCLE 2.2196 8.0436 -0.0106 20.0716
HCC1419 GDSC2 2.222 13.4913 -2.7061 33.0143
HDQ-P1 GDSC2; CTRP2; CCLE 2.502 9.498 0.8932 29.0581
Evsa-T GDSC1; GDSC2 2.5187 4.1554 2.1321 9.8946
COLO 824 GDSC1; GDSC2 2.5726 4.2694 2.137 9.6635
HCC1806 GDSC2; CTRP2; CCLE 2.891 8.7455 1.6181 25.5443
MFM-223 GDSC1; GDSC2 3.6407 5.3949 2.5376 3.9701
HCC70 GDSC2; CCLE 3.7223 7.1605 1.7253 7.4932
HCC1395 GDSC2; CTRP2; CCLE 3.7855 5.9632 3.6009 15.6924
HCC1569 GDSC2; CCLE 3.9148 11.4056 -0.2371 16.6717
YMB-1-E GDSC2 3.9317 7.6474 1.6439 8.9452
Hs 578T GDSC2; CTRP2; CCLE 3.9418 6.0169 3.7572 14.6529
HCC1500 GDSC2; CTRP2 3.9739 5.6158 3.8858 14.0961
HCC1143 GDSC2; CTRP2 4.1745 10.5498 2.0918 20.4065
MDA-MB-415 GDSC2; CCLE 4.2365 9.6212 0.8982 10.6226
MDA-MB-157 GDSC2; CTRP2; CCLE 4.3552 9.2614 2.8771 16.9397
EFM-19 GDSC2; CCLE 4.3692 9.1533 1.2263 8.7115
JIMT-1 GDSC2; CTRP2 4.3923 6.187 4.2006 11.6826
BT-483 GDSC2 4.5731 8.9441 1.4729 8.4318
MDA-MB-436 GDSC2; CCLE 4.7952 7.6636 2.2213 3.0576
MCF-7 GDSC2; CTRP2; CCLE 4.8264 10.2677 2.8481 15.924
KPL-1 CTRP2 4.8363 5.5188 4.8238 8.0907
HMC-1-8 CTRP2; CCLE 4.8584 7.9473 3.9858 11.2514
CAL-51 GDSC2; CTRP2 4.9661 7.5959 4.2544 9.9018
ZR-75-1 CTRP2; CCLE 5.099 8.6788 3.8752 11.1214
HCC38 GDSC2; CTRP2 5.0991 11.7816 2.3543 17.2395
HCC1187 GDSC1; GDSC2; CCLE 5.1521 6.7944 2.7722 0.5178
MDA-MB-361 GDSC2; CTRP2 5.1694 17.1737 -0.2652 25.6204
HCC1937 GDSC2; CTRP2 5.3214 12.6444 2.1241 17.6262
MRK-nu-1 GDSC1; GDSC2 5.4223 6.7624 2.8895 0.1858
BT-20 GDSC2; CTRP2; CCLE 5.6965 11.5837 2.9797 13.4947
MDA-MB-231 GDSC2; CTRP2 5.8623 11.9116 2.9577 13.2463
Hs 739.T CCLE 6.0845 8.2691 2.2887 0.3754
CAL-148 GDSC1; GDSC2; CTRP2 6.2702 8.818 4.841 4.6387
HCC1428 GDSC2; CTRP2 6.2977 10.8677 3.8404 8.7776
T-47D GDSC2; CTRP2; CCLE 6.3673 14.5536 2.0558 15.7507
HCC1599 GDSC1; GDSC2 7.0217 15.4174 0.0091 10.9845
CAMA-1 GDSC2; CTRP2; CCLE 7.6508 12.1721 4.1937 5.1659
CAL-120 GDSC2; CTRP2 7.6641 9.5095 5.4033 0.7594
BT-549 GDSC2; CTRP2; CCLE 9.2775 17.1671 2.8913 8.0099
BT 239 CTRP2 0.5092 4.9666 0.2601 37.6056
BT 271 CTRP2 1.919 5.21 1.7395 28.0926
BT 228 CTRP2 2.3736 2.9049 2.3736 24.4557
BT 145 CTRP2 2.4157 4.761 2.3467 24.4085
BT 330 CTRP2 2.4826 4.5304 2.4427 23.8634
BT 231 CTRP2 2.4849 8.1204 1.4463 27.3257
BT 112 CTRP2 2.5102 3.0023 2.5102 23.5456
BT164 CTRP2 2.538 2.9841 2.538 23.3603
BT 248 CTRP2 2.5775 5.7191 2.3445 23.9019
BT 139 CTRP2 2.596 9.9979 0.7718 29.1491
BT 416 CTRP2 2.6165 3.0959 2.6165 22.837
BT 172 CTRP2 2.7505 4.1077 2.7446 21.9641
BT 131 CTRP2 2.8146 9.079 1.3968 26.5189
BT 359 CTRP2 2.9109 4.8306 2.8638 21.0346
BT147 CTRP2 2.9434 3.9786 2.9421 20.6638
BT 504 CTRP2 3.0547 4.1285 3.0525 19.9252
BT 428 CTRP2 3.057 3.9037 3.0566 19.9038
BT 245 CTRP2 3.1513 4.8113 3.1191 19.3825
BT 422 CTRP2 3.1852 4.2541 3.1825 19.0573
BT 286 CTRP2 3.2301 4.0634 3.2297 18.7505
BT 444 CTRP2 3.4634 4.8773 3.4405 17.2721
BT 224 CTRP2 3.575 5.2869 3.5121 16.6654
BT 482 CTRP2 3.8209 4.7269 3.8171 14.8259
BT 216 CTRP2 3.893 5.5763 3.8057 14.6319
BT 232 CTRP2 3.9168 11.9412 1.1779 24.2651
BT 498 CTRP2 3.9288 5.4278 3.8701 14.2942
BT 328 CTRP2 4.5645 7.0635 4.0701 11.6837
BT 440 CTRP2 5.7365 12.5148 2.5492 15.1227
BT 179 CTRP2 5.7975 13.6685 2.0247 16.9949
BT 187 CTRP2 6.6112 13.5877 2.7341 12.7024
BT 320 CTRP2 6.934 11.2212 4.1548 6.378
BT 333 CTRP2 7.6286 13.2284 3.6717 7.2735
BT 159 CTRP2 7.8662 23.7618 -1.3456 23.2304
BT 340 CTRP2 8.565 21.3573 0.3736 17.5265
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 0.098 3.5816 0.0251 39.8268
Cancer Drug Sensitivity Data Curated from 67 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D283 Med GDSC1; GDSC2; CTRP2 2.6912 3.286 2.6912 22.3394
D-566MG GDSC2 2.8351 3.926 2.5573 6.4719
D-336MG GDSC1; GDSC2 2.8393 6.1008 1.5123 12.4757
D-423MG GDSC2 2.8588 5.7324 1.7119 11.6159
SF539 GDSC1; GDSC2; CTRP2 2.9385 3.8883 2.9379 20.6939
SF268 GDSC1; GDSC2; CTRP2 3.0755 4.3816 3.0675 19.8059
CAS-1 GDSC1; GDSC2; CCLE 3.2619 4.5078 2.6782 3.5424
Onda 10 GDSC1; GDSC2 3.2923 5.5737 2.1712 7.1167
D-542MG GDSC1; GDSC2 3.317 5.5981 2.1798 6.9949
AM-38 GDSC1; GDSC2 3.4853 5.0213 2.6043 3.9491
SNU-466 CTRP2 3.53 6.7203 3.09 18.3256
MOG-G-CCM GDSC2; CCLE 3.6614 6.1189 2.1954 5.1671
MOG-G-UVW GDSC2 3.6818 6.3045 2.119 6.6302
LNZTA3WT4 GDSC2 3.737 7.6869 1.4749 10.486
M059J GDSC2; CCLE 3.7466 6.3085 2.1661 5.1399
PFSK-1 GDSC2 3.7635 13.7339 -1.5208 25.0234
LN-18 GDSC2; CTRP2; CCLE 3.9147 5.1445 3.8904 14.2702
D-247MG GDSC1; GDSC2 4.0537 7.9424 1.5895 8.6709
H4 GDSC2; CCLE 4.3168 6.4908 2.4699 2.5779
Hs 683 GDSC2; CTRP2; CCLE 4.3867 5.2133 4.3776 11.0742
KNS-60 CCLE 4.3877 5.6417 2.5798 0.413
SK-MG-1 GDSC2 4.4596 7.1434 2.2557 4.07
KINGS-1 GDSC1; GDSC2 4.4661 6.8228 2.4082 3.0729
D-245MG GDSC2 4.4991 8.8037 1.4893 8.5285
GI-1 GDSC1; GDSC2; CCLE 4.507 8.1354 1.8168 5.4791
GaMG GDSC2; CTRP2; CCLE 4.5166 7.2539 3.9415 12.3129
D-502MG GDSC1; GDSC2 4.6867 17.7494 -2.7884 26.1414
1321N1 CCLE 4.7105 8.5115 1.5058 4.6925
LN-405 GDSC2 4.8342 6.6639 2.6796 1.2595
D-263MG GDSC1; GDSC2 4.8618 7.5355 2.3179 2.9289
SW1783 GDSC2; CTRP2 4.895 12.0435 2.0403 18.8849
KNS-81-FD GDSC1; GDSC2 4.9264 12.6633 -0.0884 15.6174
42-MG-BA GDSC2; CTRP2; CCLE 5.0556 8.1142 4.1027 10.2943
LN-229 GDSC2; CTRP2; CCLE 5.1741 8.9544 3.8129 11.2033
Onda 11 GDSC1; GDSC2 5.2714 7.6083 2.5029 1.5285
SW1088 GDSC2; CTRP2; CCLE 5.4002 11.0382 2.9922 14.0665
GB-1 GDSC1; GDSC2; CTRP2; CCLE 5.6345 8.5536 4.4337 7.6053
DK-MG GDSC2; CTRP2; CCLE 5.6348 10.3777 3.5276 11.3805
DBTRG-05MG GDSC2; CTRP2; CCLE 6.3428 10.3773 4.1214 7.5223
T98G GDSC2; CTRP2; CCLE 6.6416 11.6612 3.7168 8.6737
D-392MG GDSC1; GDSC2 6.7272 12.8914 0.9889 6.8663
SF126 GDSC1; GDSC2; CTRP2; CCLE 7.1239 11.684 4.0658 6.4445
KALS-1 GDSC1; GDSC2; CTRP2; CCLE 7.3526 11.1306 4.4915 4.3911
CCF-STTG1 CTRP2 7.4207 9.7284 5.1835 1.6709
YKG-1 GDSC2; CTRP2; CCLE 7.4339 11.3407 4.4455 4.4634
GMS-10 CTRP2; CCLE 7.4644 10.491 4.8635 2.7994
KG-1-C CTRP2 7.4781 13.465 3.4505 8.3845
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 7.4996 19.5176 -1.6147 16.6529
NMC-G1 GDSC1; GDSC2; CTRP2 7.5029 9.318 5.404 0.8692
KNS-81 CTRP2; CCLE 7.5474 13.861 3.3069 8.8487
TM-31 CTRP2 7.64 11.5103 4.4992 3.9828
SNU-1105 CTRP2 7.7049 9.5043 5.4245 0.6748
U-87MG ATCC GDSC1; GDSC2; CTRP2; CCLE 7.7386 9.1053 5.5932 0.2634
SF295 GDSC2; CTRP2; CCLE 7.7953 9.1435 5.6017 0.2291
GOS-3 CTRP2 7.7979 14.3423 3.2504 8.6894
SNB-75 GDSC1; GDSC2; CTRP2 7.8305 20.7559 0.119 19.4725
U-118MG GDSC2; CTRP2; CCLE 8.098 11.2941 4.8689 2.1135
ONS-76 GDSC1; GDSC2; CTRP2; CCLE 8.1655 12.7077 4.2707 4.2154
Daoy GDSC2; CTRP2; CCLE 8.2589 12.9248 4.2278 4.2672
YH-13 GDSC2; CTRP2 8.3083 14.059 3.7302 6.1036
SNU-201 CTRP2 8.45 19.6391 1.1327 15.3482
8-MG-BA GDSC1; GDSC2; CTRP2; CCLE 8.7351 14.2232 3.9204 4.8628
A-172 GDSC2; CTRP2; CCLE 8.8496 16.6306 2.8669 8.6594
M059K CTRP2 8.9485 17.3273 2.601 9.504
U-251MG GDSC2; CTRP2 9.1669 19.5297 1.6932 12.4039
KNS-42 GDSC1; GDSC2; CTRP2; CCLE 9.2966 16.4397 3.2423 6.7038
Becker GDSC1; GDSC2; CTRP2 12.7112 23.9581 1.844 7.7105
⏷ Show the Full List of 67 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC2 1.8128 7.4582 -0.1076 25.5983
ETK-1 GDSC1; GDSC2 1.8926 5.4946 0.8963 19.3262
TGBC1TKB GDSC1; GDSC2 5.9655 15.9389 -0.9423 17.0568
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP2; CCLE 2.6908 4.3651 2.6724 22.4039
RL95-2 GDSC1; GDSC2; CTRP2; CCLE 3.0761 7.74 2.224 22.8483
MFE-280 GDSC2; CCLE 3.585 7.7967 1.2998 10.0152
JHUEM-3 CTRP2 3.9515 14.6277 -0.0957 27.9628
JHUEM-7 CTRP2 4.1859 6.122 3.9944 13.0542
JHUEM-1 CTRP2 4.6118 7.0835 4.1118 11.393
EN GDSC2; CTRP2; CCLE 4.6819 6.8946 4.2623 10.6194
HEC-50B CTRP2 4.7863 8.0971 3.8449 11.9983
ESS-1 GDSC2; CTRP2; CCLE 5.0698 10.2506 3.0826 14.4272
HEC-151 CTRP2; CCLE 5.105 10.7425 2.8729 15.1913
TEN CCLE 5.299 8.4286 1.8775 2.2202
MFE-296 GDSC2; CTRP2; CCLE 5.7525 10.464 3.5868 10.8928
EFE-184 CTRP2; CCLE 6.1115 15.6751 1.2848 18.9832
HEC-108 CTRP2 6.2516 10.6458 3.914 8.5563
HEC-251 CTRP2; CCLE 6.8232 13.8729 2.7587 12.2236
MFE-319 GDSC2; CTRP2; CCLE 6.8755 13.5784 2.9456 11.3944
AN3-CA GDSC2; CTRP2; CCLE 7.0894 11.6977 4.0342 6.6268
HEC-59 CTRP2; CCLE 7.2939 9.588 5.1738 1.8366
HEC-265 CTRP2; CCLE 7.5352 8.6918 5.6643 0.2006
HEC-1-A CTRP2; CCLE 8.0616 16.9594 2.1631 12.4095
KLE GDSC2; CTRP2; CCLE 8.1633 15.6803 2.8577 9.6637
HEC-1-B CTRP2; CCLE 8.3363 10.6165 5.2696 0.7208
HEC-6 CTRP2; CCLE 8.4116 15.1684 3.2724 7.7248
Ishikawa (Heraklio) 02 ER- CTRP2; CCLE 7.4094 8.8496 5.5504 0.5129
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW13 GDSC2 1.5362 6.0177 0.3 24.6807
LB2241-RCC GDSC1; GDSC2 1.6055 12.5878 -2.8092 34.6259
LB996-RCC GDSC1; GDSC2 1.7555 13.7338 -3.2409 35.0808
KTCTL-140 GDSC2 1.8231 4.0577 1.4396 17.1429
BB65-RCC GDSC1; GDSC2 2.0391 4.0846 1.659 14.4558
KTCTL-195 GDSC2 2.285 4.1205 1.9039 12.5339
KTCTL-1M GDSC2 2.3615 6.5381 0.857 18.4771
NCC010 GDSC2 2.4266 5.3323 1.4993 14.4232
A-704 GDSC2 2.5103 4.4246 2.0041 11.048
CAL-54 GDSC2; CTRP2 2.7618 11.5446 0.2389 30.1978
786-O GDSC2; CTRP2; CCLE 2.8149 5.6219 2.6256 22.1685
SW156 GDSC2 2.9634 8.2121 0.572 18.0561
TK-10 GDSC1; GDSC2 3.1725 11.9426 -1.1136 24.6234
NCC021 GDSC2 3.2156 6.0545 1.8661 9.5249
VMRC-RCW GDSC2; CTRP2; CCLE 3.2497 5.8696 3.0403 19.3463
HA7-RCC GDSC1; GDSC2 3.2903 6.7942 1.5594 10.8385
KMRC-3 CTRP2 3.3513 5.2127 3.2835 18.1721
LB1047-RCC GDSC1; GDSC2 3.3855 11.5298 -0.7292 22.4687
KTCTL-26A GDSC2 3.4 8.3963 0.8495 15.1549
UO-31 GDSC2; CTRP2 3.4992 9.7121 1.8167 23.1546
RXF 393L GDSC1; GDSC2 3.538 7.0247 1.6474 9.6248
KTCTL-13 GDSC2 3.5423 11.2435 -0.4568 21.4188
KMRC-1 GDSC2; CTRP2; CCLE 3.8378 5.7896 3.7008 15.1744
TUHR14TKB CTRP2 4.2942 6.5626 3.9713 12.8194
KMRC-20 GDSC2; CTRP2 4.3137 5.8046 4.2153 11.8699
KTCTL-21 GDSC2 4.8666 15.2753 -1.4213 21.817
SN12C GDSC2 5.063 12.5752 0.0538 15.046
KMRC-2 CTRP2; CCLE 5.4102 11.03 3.0052 13.9927
769-P GDSC2; CTRP2; CCLE 5.7242 12.2261 2.6828 14.6232
BFTC-909 GDSC2; CTRP2; CCLE 5.7888 9.5267 4.0859 8.7371
Caki-2 CTRP2; CCLE 6.5264 16.4538 1.2357 18.3408
VMRC-RCZ GDSC2; CTRP2; CCLE 6.5839 11.8005 3.6027 9.2456
SNU-1272 CTRP2 7.1133 13.1284 3.349 9.3753
ACHN GDSC2; CTRP2; CCLE 7.2118 13.941 3.0218 10.5186
A-498 GDSC2; CTRP2 7.5555 13.9328 3.2776 8.9522
OS-RC-2 GDSC1; GDSC2; CTRP2 8.1184 17.7634 1.8106 13.5799
RCC10RGB GDSC1; GDSC2; CTRP2 8.5534 19.9249 1.0678 15.3963
Caki-1 GDSC2; CTRP2 8.7883 18.5012 1.9279 12.1436
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DiFi GDSC2 -1.1734 2.1349 -1.3183 45.4615
CCK-81 GDSC2; CTRP2; CCLE -0.5543 5.6199 -1.0456 44.7538
SNU-175 GDSC2; CTRP2 -0.1249 14.3604 -3.943 45.4302
NCI-H508 GDSC2; CTRP2 0.4946 7.5696 -0.488 39.3881
HT115 GDSC2; CTRP2 0.6213 3.6782 0.4081 27.3911
SW48 GDSC2; CTRP2; CCLE 1.2357 14.4692 -2.6304 40.1756
SW403 CCLE 2.0319 8.8753 -0.779 22.1655
LS513 GDSC1; GDSC2; CTRP2; CCLE 2.0861 6.908 1.4613 28.505
HCT 15 GDSC2; CTRP2; CCLE 2.473 4.2923 2.4511 23.8666
HT-55 GDSC2; CTRP2 2.5194 10.0944 0.6509 29.7346
GP2d CTRP2 2.5204 10.9611 0.2642 30.8253
SNU-1033 CTRP2 2.6289 6.4291 2.2052 24.2382
CW-2 GDSC1; GDSC2; CTRP2 2.7099 6.701 2.207 23.9861
C2BBe1 GDSC1; GDSC2; CTRP2; CCLE 2.7554 8.3544 1.6384 25.8673
HCC2998 GDSC1; GDSC2 2.7626 4.2722 2.3266 7.8602
SNU-C2B GDSC2; CCLE 2.764 7.9799 0.5131 16.0575
LoVo GDSC2; CTRP2 2.9102 10.941 0.6648 28.5644
COLO 320 CTRP2; CCLE 2.9139 4.4805 2.8965 20.914
T84 GDSC2; CTRP2; CCLE 3.003 5.3297 2.8895 20.6503
SNU-407 GDSC2; CTRP2 3.1562 9.7465 1.4546 25.3551
CaR-1 GDSC2 3.1874 5.6829 2.0276 8.5927
SNU-61 GDSC2; CTRP2 3.2674 7.9835 2.3289 21.9181
SW1463 GDSC2 3.3082 11.3282 -0.6927 23.1359
NCI-H747 GDSC1; GDSC2; CTRP2; CCLE 3.5838 11.0084 1.3003 24.7185
SW1116 GDSC2 3.5909 8.2932 1.0567 13.3997
COLO 678 GDSC2; CTRP2; CCLE 3.6648 13.5645 0.1548 28.0011
GP5d GDSC2 3.7214 9.6906 0.4641 16.3718
COLO 320HSR GDSC1; GDSC2 3.7779 6.6115 2.04 6.6426
SK-CO-1 GDSC2; CTRP2; CCLE 3.8399 7.2442 3.2303 16.9129
SNU-81 GDSC2; CTRP2 3.902 5.2957 3.8601 14.415
LS1034 GDSC1; GDSC2; CTRP2 3.9947 6.2503 3.7481 14.5261
SW948 GDSC2; CTRP2 3.996 14.7387 -1.8349 22.218
OUMS-23 CTRP2 4.0772 5.0701 4.0657 13.1444
SNU-C1 GDSC1; GDSC2 4.1484 6.1802 2.5089 3.0723
SW837 GDSC2 4.1948 6.8099 2.2408 4.6837
SW480 CCLE 4.208 6.597 2.0807 2.6575
HCC-56 CTRP2; CCLE 4.2591 7.738 3.4685 14.8506
CL-11 GDSC1; GDSC2; CTRP2 4.3507 6.5414 4.0399 12.3994
SNU-283 GDSC2 4.3988 16.0586 -2.1727 25.5179
LS180 GDSC2; CTRP2 4.5304 10.9413 2.2427 18.9742
SW626 GDSC2 4.621 7.2365 2.3121 3.4575
SNU-C5 GDSC2; CTRP2 4.752 8.9187 3.4265 13.7726
HT-29 GDSC2; CTRP2; CCLE 4.8558 8.1052 3.9102 11.5627
NCI-H716 GDSC1; GDSC2; CTRP2 4.8751 7.9871 3.9841 11.2167
SW620 GDSC2; CTRP2; CCLE 5.5924 8.0609 4.6384 6.8443
LS123 GDSC1; GDSC2; CTRP2; CCLE 5.6847 12.3322 2.596 15.0461
SNU-503 CTRP2 5.7396 18.1743 -0.2764 24.4576
SNU-C2A CTRP2; CCLE 6.016 10.6774 3.7042 9.8793
RCM-1 [Human ESC] GDSC2; CTRP2 6.1899 12.541 2.9166 12.7678
COLO201 CTRP2; CCLE 6.2149 12.9803 2.7175 13.5106
HCT 8 CTRP2 6.9804 11.5673 4.0188 6.8624
DLD-1 CTRP2 7.483 8.6314 5.6657 0.2153
SNU-C4 CTRP2 7.5926 16.3426 2.1218 13.3187
HCT 116 GDSC2; CTRP2; CCLE 7.7113 11.7863 4.4153 4.2181
SW1417 GDSC2; CTRP2; CCLE 7.7308 17.4488 1.6794 14.6707
LS411N GDSC1; GDSC2; CTRP2; CCLE 7.8094 9.286 5.5547 0.3127
MDST8 GDSC1; GDSC2; CTRP2 8.046 9.3695 5.6161 0.1421
RKO GDSC1; GDSC2; CTRP2; CCLE 8.1139 10.0482 5.3932 0.5338
KM12 GDSC1; GDSC2; CTRP2 8.6736 10.1267 5.5798 0.0819
COLO205 GDSC2; CTRP2; CCLE 8.7677 15.6834 3.2615 7.2921
⏷ Show the Full List of 60 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 3.7673 5.468 2.5936 3.3463
Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-5 CTRP2; CCLE 0.8951 7.8523 -0.1552 37.176
HuH-6 CTRP2 2.1892 5.5978 1.9502 26.5028
SNU-761 CTRP2 2.549 3.7994 2.5465 23.295
SNU-182 CTRP2; CCLE 3.1705 4.1164 3.1694 19.1499
Hep-G2/C3A GDSC2; CCLE 3.4028 6.4063 1.8466 7.5839
SNU-398 GDSC2; CCLE 3.4339 5.1067 2.521 3.9598
JHH-7 GDSC2; CCLE 3.9945 7.7215 1.6544 7.2843
Hep-G2 CTRP2; CCLE 4.1293 5.7791 4.0204 13.1343
HLE GDSC2; CCLE 4.2543 7.3986 1.9986 5.0158
SNU-449 GDSC2; CTRP2; CCLE 4.2818 8.1726 3.3019 15.4461
SNU-387 GDSC2; CTRP2; CCLE 4.3478 11.1646 1.9621 20.4604
HLF CTRP2; CCLE 4.6308 6.9794 4.1742 11.0997
Huh-7 GDSC2 4.8773 8.7674 1.7606 6.1461
JHH-4 GDSC2; CTRP2; CCLE 5.2173 11.3483 2.6752 15.7288
HuH-1 GDSC2; CTRP2; CCLE 5.9937 10.1833 3.9326 8.9699
PLC/PRF/5 CTRP2; CCLE 6.3475 12.7658 2.9328 12.4033
JHH-2 GDSC2; CTRP2; CCLE 6.8169 14.3342 2.5244 13.1456
JHH-1 GDSC2; CTRP2 6.8531 15.9599 1.7434 15.976
SNU-423 GDSC2; CTRP2; CCLE 6.9298 12.6478 3.4484 9.2792
JHH-6 GDSC2; CTRP2; CCLE 7.1864 8.0585 5.7582 0.1448
SNU-475 CTRP2; CCLE 7.4075 11.9416 4.1399 5.7204
SK-HEP-1 GDSC2; CTRP2; CCLE 7.8928 9.1279 5.6444 0.1372
Hep 3B2.1-7 GDSC2; CTRP2; CCLE 8.1103 15.1992 3.0534 8.9922
⏷ Show the Full List of 23 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 227 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LC-1F CTRP2 -3.7847 47.2102 -28.071 48.2054
NCI-H1648 GDSC1; GDSC2; CCLE -1.2483 4.5793 -2.058 40.5111
HCC2935 CTRP2; CCLE -0.9255 2.9103 -0.9887 46.5313
NCI-H2170 GDSC2; CTRP2; CCLE -0.7993 4.1104 -0.999 45.8936
NCI-H3255 GDSC2; CCLE -0.1679 5.4981 -1.2421 33.3272
Calu-3 GDSC2; CTRP2; CCLE -0.1051 3.6859 -0.2002 41.2227
NCI-H1666 GDSC1; GDSC2; CTRP2; CCLE 0.3995 4.5005 0.2264 38.1152
RERF-LC-Sq1 GDSC2 0.6042 7.2643 -1.2042 35.0157
HCC4006 CTRP2; CCLE 0.6575 2.739 0.6511 35.9091
PaCa-3 GDSC2 0.6648 4.8454 -0.1002 30.4804
PC-14 GDSC2; CCLE 0.8589 3.3529 0.6254 21.6076
EMC-BAC-1 GDSC2 0.8746 5.0847 0.0254 28.9118
HCC827 GDSC2; CTRP2; CCLE 1.0631 3.7634 1.0212 33.3245
NCI-H358 GDSC2; CTRP2; CCLE 1.4956 6.8259 0.8467 32.3952
NCI-H1623 GDSC2; CTRP2 1.5581 8.0819 0.4726 33.2698
EKVX GDSC1; GDSC2; CTRP2 1.6098 11.5452 -0.9209 36.3645
COR-L105 GDSC2; CTRP2; CCLE 1.8117 6.2354 1.3716 29.6813
NCI-H1304 GDSC1 1.8123 3.5125 0.3389 2.9027
DV-90 CTRP2; CCLE 1.8219 5.9506 1.4616 29.3484
NCI-H322 CTRP2; CCLE 1.8253 6.0846 1.4289 29.4469
NCI-H322M GDSC1; GDSC2 1.8492 6.8783 0.205 23.1735
LUDLU-1 CTRP2; CCLE 1.8546 8.7921 0.5108 32.1897
IST-SL1 GDSC1; GDSC2 2.1948 3.7215 1.9635 12.1331
SK-MES-1 GDSC2; CTRP2; CCLE 2.3621 7.1941 1.662 26.9645
DMS 454 CTRP2 2.5027 7.7391 1.6131 26.7049
NCI-H1435 GDSC2; CTRP2 2.5341 5.1107 2.4221 23.7678
NCI-H187 GDSC1 2.579 4.161 0.4618 0.9521
NCI-H2171 GDSC1; GDSC2 2.6037 3.4546 2.4983 7.5033
NCI-H1385 CTRP2 2.6277 3.5963 2.6273 22.7637
NCI-H1781 GDSC2 2.6504 6.0956 1.3422 14.5922
HCC95 CTRP2 2.6523 8.0776 1.6408 26.1622
EBC-1 GDSC2; CTRP2; CCLE 2.6911 3.4634 2.691 22.3403
COR-L279 GDSC2 2.6956 5.0791 1.8791 11.1336
LXF 289 GDSC1; GDSC2; CTRP2 2.6995 5.3839 2.5508 22.7939
COR-L303 GDSC2 2.7059 3.6247 2.5481 7.0482
NCI-H211 GDSC1; GDSC2; CTRP2; CCLE 2.8086 3.9575 2.8064 21.5647
HCC1588 CTRP2 2.8361 4.8783 2.779 21.5675
COLO 677 CCLE 2.8385 4.5718 2.0758 5.4247
NCI-H1734 GDSC2; CTRP2 2.8917 4.21 2.8855 21.0246
NCI-H2286 CCLE 2.9087 4.9014 1.9722 5.8007
NCI-H1963 GDSC1; GDSC2 2.9319 4.3682 2.4465 6.5571
NCI-H2795 GDSC2 2.9368 5.7528 1.7723 10.9847
NCI-H446 GDSC1; GDSC2; CTRP2 2.9761 4.9914 2.9136 20.653
NCI-H2731 GDSC2 2.9986 4.6686 2.3632 7.0802
Ms-1 GDSC1; GDSC2 3.0321 4.9929 2.2341 7.5102
Lu-135 GDSC2 3.058 4.7896 2.358 6.9164
IST-SL2 GDSC1; GDSC2 3.0874 5.6783 1.943 9.1091
NCI-H1341 GDSC2; CTRP2; CCLE 3.1107 3.9592 3.1103 19.5462
CAL-12T GDSC2; CTRP2; CCLE 3.1386 9.6646 1.4733 25.3404
CPC-N GDSC1; GDSC2 3.1686 4.9948 2.3545 6.3585
NCI-H2081 GDSC1; GDSC2; CTRP2 3.1736 5.5483 3.0316 19.6143
NCI-H1693 GDSC2; CTRP2; CCLE 3.1849 5.9186 2.9572 19.843
NCI-H1437 GDSC2 3.1858 8.9085 0.4144 18.2149
Lu-65 GDSC1; GDSC2; CTRP2 3.2058 6.674 2.7543 20.5174
LCLC-97TM1 GDSC2 3.2182 5.2409 2.2747 6.9386
COR-L23 GDSC2; CCLE 3.2434 4.2839 2.774 3.085
UMC-11 GDSC2 3.2525 5.6601 2.0945 7.9745
COR-L321 GDSC2 3.2867 5.4383 2.2343 6.989
A-427 GDSC2 3.3534 8.6611 0.6785 16.2614
NCI-H847 GDSC1; GDSC2 3.3546 4.7689 2.6255 4.1661
NCI-H146 GDSC2 3.355 6.0748 1.973 8.4412
HCC33 GDSC1; GDSC2 3.433 4.7758 2.6854 3.5902
NCI-H2106 CTRP2 3.4368 4.6229 3.4282 17.401
SBC-1 GDSC1; GDSC2 3.4426 4.8749 2.6435 3.8202
NCI-H1755 GDSC2; CTRP2 3.4577 9.502 1.8699 23.0755
NCI-H1876 GDSC1; GDSC2 3.4634 4.8179 2.6883 3.4935
NCI-H290 GDSC2 3.4812 8.4041 0.9123 14.5555
NCI-H1155 GDSC1; GDSC2; CTRP2; CCLE 3.4894 4.58 3.4837 17.0409
NCI-H128 GDSC1 3.5069 5.2846 0.4212 0.4462
NCI-H661 GDSC2; CTRP2; CCLE 3.5371 5.679 3.3986 17.1818
NCI-H1568 GDSC2; CTRP2; CCLE 3.5531 7.674 2.7557 19.5182
NCI-H810 GDSC2; CTRP2; CCLE 3.5939 4.3225 3.5935 16.3268
SW1271 GDSC2; CTRP2; CCLE 3.652 4.9659 3.6305 16.0109
SW900 CCLE 3.6724 5.703 2.1594 3.1285
NCI-H2087 GDSC2; CTRP2; CCLE 3.6959 5.4498 3.6158 15.9195
MOR/CPR CTRP2; CCLE 3.734 4.9622 3.7163 15.4515
Lu-165 GDSC1; GDSC2 3.7372 5.376 2.617 3.2733
NCI-H1993 GDSC2 3.7838 5.9972 2.3469 4.9529
NCI-H1688 GDSC2 3.7911 7.7551 1.4832 10.2916
NCI-H209 GDSC1; GDSC2 3.7937 5.469 2.6116 3.1826
NCI-H2141 GDSC1; GDSC2; CTRP2 3.8004 5.3954 3.7372 15.165
NCI-H2804 GDSC2 3.829 7.7438 1.5181 9.9789
NCI-H835 GDSC2 3.8504 7.3581 1.7255 8.6491
NCI-H250 GDSC2 3.8655 8.1684 1.3355 10.9914
NCI-H64 GDSC1; GDSC2 3.8667 5.5901 2.6035 3.0775
NCI-H1869 GDSC1; GDSC2; CTRP2; CCLE 3.8805 13.5742 0.3528 26.8999
NCI-H2126 CTRP2 3.8929 9.2258 2.4338 19.8329
NCI-H1975 GDSC1; GDSC2; CCLE 3.9226 6.2675 2.3148 4.0205
Lu-134-A GDSC1; GDSC2 3.9391 8.2435 1.3547 10.3288
COR-L32 GDSC2 3.9534 6.5333 2.2072 5.4184
COR-L311 GDSC2 3.9541 5.8491 2.5384 3.396
NCI-H748 GDSC1; GDSC2 3.9572 6.8491 2.0557 6.1257
NCI-H69 GDSC1; GDSC2; CTRP2 3.9655 7.5853 3.2263 16.5817
RERF-LC-KJ GDSC2 3.9657 9.1487 0.9261 13.1352
HCC44 GDSC2; CTRP2; CCLE 3.975 5.612 3.8877 14.0859
NCI-H513 GDSC2 3.975 8.2838 1.362 10.5477
LK-2 GDSC2 3.9806 10.0669 0.4815 15.5644
LB647-SCLC GDSC1; GDSC2 3.9891 6.3022 2.3445 4.3414
GLC-82 CCLE 4.0422 7.1525 1.7149 4.7555
NCI-H1436 GDSC1; GDSC2 4.0591 5.7136 2.6703 2.3269
NCI-H2291 GDSC2; CTRP2 4.0614 12.4042 1.0913 24.1865
NCI-H2373 GDSC2 4.0789 6.6257 2.2504 4.8725
NCI-H2066 GDSC2 4.1207 7.2394 1.9823 6.4146
EPLC-272H GDSC2; CTRP2 4.1511 12.6398 1.061 24.0633
NCI-H524 GDSC1; GDSC2; CTRP2 4.1741 5.3813 4.1388 12.5795
NCI-H522 GDSC2; CTRP2; CCLE 4.1809 10.8767 1.9417 20.9443
NCI-H1092 GDSC1; GDSC2; CCLE 4.2233 6.2064 2.5438 2.3654
NCI-H2803 GDSC2 4.2269 9.386 1.0071 11.9972
NCI-H510A GDSC1; GDSC2 4.252 6.9293 2.222 4.516
NCI-H520 GDSC2; CTRP2; CCLE 4.2709 5.5994 4.2097 12.0243
LC-2/ad GDSC1; GDSC2 4.2831 9.3529 1.0652 11.1526
NCI-H720 GDSC1; GDSC2 4.3028 5.6986 2.8172 1.1908
NCI-H2029 GDSC2; CTRP2 4.3138 8.9918 2.9617 16.7093
COR-L95 GDSC1; GDSC2; CTRP2 4.323 9.9747 2.5091 18.4568
NCI-H2196 GDSC1; GDSC2 4.3241 6.5636 2.4406 3.1381
NCI-H1836 GDSC1; GDSC2 4.3248 5.9042 2.7397 1.5419
SHP-77 GDSC1; GDSC2; CTRP2; CCLE 4.3358 6.5843 4.0086 12.5595
NCI-H2810 GDSC2 4.3697 8.1602 1.7106 7.4993
NCI-H1184 CTRP2; CCLE 4.3805 6.6738 4.0247 12.371
NCI-H2461 GDSC2 4.4019 9.7874 0.9391 11.9526
SBC-3 GDSC2 4.405 6.6317 2.4589 3.0024
LK2 CTRP2 4.4146 5.2394 4.4049 10.8904
NCI-H596 GDSC2 4.4383 7.0057 2.3065 3.8153
NCI-H2085 GDSC2; CTRP2; CCLE 4.4667 11.1603 2.0765 19.7507
NCI-H1770 GDSC1; GDSC2 4.4885 10.0214 0.8877 11.6544
HOP-92 GDSC2; CTRP2 4.5027 8.627 3.3181 14.8199
NCI-H2405 GDSC2; CTRP2 4.5053 10.7115 2.3303 18.7012
NCI-H345 GDSC1; GDSC2 4.515 5.7097 2.9156 0.5565
NCI-H1581 GDSC1; GDSC2; CTRP2; CCLE 4.5299 6.0831 4.3808 10.6124
NCI-H1573 GDSC2; CCLE 4.5326 12.7991 -0.4495 16.2071
LC-1/sq GDSC2 4.5505 10.4227 0.7361 12.7238
NCI-H2369 GDSC2 4.5583 7.2282 2.2777 3.762
HCC1833 CTRP2 4.576 8.7407 3.3379 14.5584
NCI-H647 GDSC2; CTRP2; CCLE 4.5853 7.2446 4.0172 11.833
NCI-H1915 GDSC2; CTRP2; CCLE 4.6283 6.2742 4.4306 10.1363
NCI-H3122 GDSC2 4.6354 7.9932 1.9692 5.4043
NCI-H2444 GDSC2; CTRP2; CCLE 4.6412 8.5721 3.4808 13.8238
SK-LU-1 GDSC2; CTRP2; CCLE 4.6474 6.7434 4.2848 10.6289
NCI-H2818 GDSC2 4.7086 10.7608 0.6853 12.6237
ABC-1 GDSC2 4.718 7.6319 2.1894 3.9816
NCI-H292 GDSC2; CTRP2 4.7291 12.1859 1.8187 20.079
HCC2279 CTRP2 4.7363 8.9273 3.4072 13.8887
Lu-99A GDSC2 4.7407 7.287 2.3598 2.9964
Hs 229.T CCLE 4.7847 8.0845 1.746 3.4291
NCI-H82 GDSC1; GDSC2 4.8204 12.7293 -0.1989 16.3802
NCI-H1105 GDSC2 4.8412 7.6244 2.2661 3.347
NCI-H2869 GDSC2 4.8535 7.2168 2.4541 2.3284
NCI-H2122 GDSC2; CTRP2; CCLE 4.8745 7.9884 3.9828 11.2233
EMC-BAC-2 GDSC2 4.8791 16.4007 -1.9694 23.6952
NCI-H2591 GDSC2 4.8803 10.0041 1.1735 9.5176
NCI-H2722 GDSC2 4.935 7.0131 2.5842 1.5842
NCI-H2347 GDSC2 4.9614 7.1222 2.5516 1.7066
NCI-H1694 GDSC1; GDSC2; CCLE 4.9624 7.0295 2.591 1.267
LC-1/sq-SF CTRP2; CCLE 5.0515 8.2395 4.0394 10.5617
COLO 699 CTRP2; CCLE 5.0653 9.7664 3.3155 13.4914
NCI-H2135 GDSC1; GDSC2 5.1322 7.1588 2.62 1.1746
DMS 114 GDSC1; GDSC2; CTRP2; CCLE 5.1369 7.9843 4.2432 9.5259
NCI-H1048 GDSC2; CCLE 5.1424 7.6469 2.4219 1.7564
VMRC-LCD GDSC2; CTRP2; CCLE 5.1467 7.8118 4.3341 9.1326
NCI-H740 GDSC2 5.1594 8.8064 1.9176 4.7431
NCI-H841 GDSC2; CTRP2 5.1892 9.8512 3.3885 12.9141
NCI-H2023 GDSC2; CTRP2; CCLE 5.224 11.3812 2.6648 15.755
DMS 53 GDSC2 5.2365 6.9417 2.7518 0.6341
NCI-H2227 GDSC1; GDSC2 5.2458 7.1643 2.6698 0.8859
NCI-H2110 GDSC2; CTRP2 5.3114 13.934 1.4732 19.9986
NCI-H441 GDSC2; CTRP2; CCLE 5.3331 11.6449 2.6313 15.6495
NCI-H727 GDSC2; CTRP2; CCLE 5.3501 9.7934 3.5639 11.8376
NCI-H1373 CTRP2; CCLE 5.3548 8.2066 4.3459 8.5923
NCI-H2342 GDSC2; CTRP2 5.3885 10.4575 3.2699 12.9626
Lu-139 GDSC1; GDSC2 5.4835 7.4132 2.6765 0.6966
NCI-H23 GDSC1; GDSC2; CTRP2; CCLE 5.4857 9.8676 3.6493 11.1908
NCI-H2172 GDSC2; CTRP2; CCLE 5.5073 7.9041 4.6362 7.0446
SW1573 GDSC2; CCLE 5.5573 8.8486 2.124 2.538
NCI-H1650 GDSC1; GDSC2; CTRP2; CCLE 5.5952 12.4096 2.4801 15.6839
NCI-H2595 GDSC2 5.704 8.5207 2.3371 1.8635
HCC366 GDSC2; CTRP2 5.7539 14.7466 1.4489 19.1468
NCI-H889 CTRP2 5.8187 11.6401 3.0563 12.936
Lu-99 CTRP2; CCLE 5.8457 9.5393 4.1287 8.4425
COR-L88 GDSC1; GDSC2; CTRP2 5.8705 11.2399 3.3003 11.837
T3M-10 CTRP2; CCLE 5.8768 11.1762 3.3376 11.6713
NCI-H1944 GDSC2; CTRP2; CCLE 5.9285 16.5909 0.6743 21.3292
A-549 GDSC2; CTRP2; CCLE 6.0329 14.4143 1.8498 17.1601
DMS 273 GDSC2; CTRP2 6.108 9.6847 4.2769 7.3065
NCI-H1792 GDSC2; CTRP2; CCLE 6.1222 11.2507 3.5058 10.4973
HCC15 GDSC2; CTRP2; CCLE 6.1442 11.8003 3.2492 11.5095
NCI-H526 GDSC1; GDSC2; CTRP2 6.1542 8.7674 4.7733 5.1345
NCI-H1703 GDSC2; CTRP2; CCLE 6.2207 11.1672 3.6284 9.8027
NCI-H2030 GDSC2; CTRP2; CCLE 6.2401 17.3079 0.5749 21.0144
HARA [Human squamous cell lung carcinoma] GDSC2; CTRP2; CCLE 6.2492 14.9526 1.7598 17.0576
NCI-H1838 GDSC1; GDSC2; CTRP2 6.2604 12.49 2.9998 12.2989
NCI-H1793 GDSC2; CTRP2; CCLE 6.3 17.4653 -1.4478 16.2962
ChaGo-K-1 GDSC2; CTRP2 6.357 11.4961 3.5745 9.7718
SBC-5 GDSC2; CTRP2; CCLE 6.4608 11.9 3.456 10.0703
COLO 668 GDSC1; GDSC2 6.5326 16.0253 -0.5943 14.4977
IA-LM GDSC2; CTRP2; CCLE 6.643 10.814 4.1382 6.9252
NCI-H1395 CTRP2 6.6733 16.1999 1.4808 17.2293
Calu-1 CTRP2; CCLE 6.7341 13.113 3.0671 11.1586
NCI-H1355 GDSC1; GDSC2; CTRP2; CCLE 6.9842 14.639 2.503 12.9306
RERF-LC-Ad2 CTRP2 7.0009 14.6172 2.5267 12.8103
RERF-LC-MS GDSC2; CTRP2; CCLE 7.0496 12.4019 3.6595 8.2207
HOP-62 GDSC1; GDSC2; CTRP2 7.0789 14.217 2.785 11.6746
DMS 79 GDSC1; GDSC2; CTRP2 7.0994 12.5761 3.6107 8.3386
BEN GDSC2; CTRP2 7.1116 8.1165 5.7057 0.282
NCI-H1651 GDSC2; CTRP2; CCLE 7.1649 15.2914 2.3183 13.3159
RERF-LC-Ad1 CTRP2 7.2493 8.2325 5.7193 0.1953
NCI-H2009 GDSC2; CTRP2; CCLE 7.3381 15.8643 2.1665 13.5833
Sq-1 CTRP2; CCLE 7.3592 14.7398 2.7379 11.3849
KNS-62 GDSC2; CTRP2; CCLE 7.4587 12.6305 3.8425 6.8411
LOU-NH91 GDSC2; CTRP2; CCLE 7.5945 17.7721 1.417 15.804
NCI-H838 GDSC2; CTRP2 7.6774 13.0411 3.7957 6.7086
NCI-H196 GDSC2; CTRP2 7.7972 9.3088 5.5411 0.3453
LCLC-103H GDSC2; CTRP2; CCLE 7.8277 13.3528 3.7483 6.6823
NCI-H226 GDSC1; GDSC2; CTRP2; CCLE 7.8532 10.4803 5.0907 1.5858
NCI-H460 GDSC2; CTRP2; CCLE 7.9551 8.9903 5.7138 0.0539
HCC1171 CTRP2 8.1111 16.6159 2.3664 11.5872
Calu-6 GDSC1; GDSC2; CTRP2; CCLE 8.2796 12.7319 4.3288 3.866
HCC1195 CTRP2 8.3051 10.0067 5.487 0.2712
HCC2108 CTRP2 8.3647 12.275 4.5843 2.8471
NCI-H2228 GDSC2; CTRP2; CCLE 8.3691 15.885 2.9008 9.2002
NCI-H650 GDSC2; CTRP2; CCLE 8.383 12.0223 4.7059 2.406
HCC78 GDSC2; CTRP2; CCLE 8.3964 13.6875 3.9598 5.1151
NCI-H1339 CTRP2; CCLE 8.4257 12.4887 4.5237 3.0005
NCI-H1299 GDSC2; CTRP2; CCLE 8.632 11.1755 5.1817 0.7836
RERF-LC-A1 CTRP2; CCLE 9.1406 14.7793 3.9078 4.4608
NCI-H1563 GDSC2; CTRP2; CCLE 11.0784 22.3807 1.5932 10.2447
HCC1438 CTRP2 12.6904 27.5573 0.1931 12.538
Hs 888.Lu CTRP2 6.672 11.3422 3.8986 7.8695
⏷ Show the Full List of 227 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 2.7213 4.0447 2.3885 7.651
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 2.6078 8.6669 1.3548 27.2647
Cancer Drug Sensitivity Data Curated from 50 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 3.3456 4.6383 3.3338 18.0192
JHOS-4 GDSC2; CCLE 1.8676 5.9002 0.6843 17.832
SNU-119 CTRP2 2.2901 7.2663 1.5587 27.5395
Caov-4 GDSC2 2.6674 6.1041 1.3537 14.4646
OC 314 GDSC2; CTRP2; CCLE 2.7321 4.051 2.7273 22.0832
RMG-I GDSC2; CTRP2 3.0478 11.2371 0.6652 28.178
OVCAR-3 GDSC2; CCLE 3.0487 7.5068 0.9976 12.8803
OVMANA CCLE 3.0778 5.8814 1.6236 7.266
COV434 CTRP2 3.3634 4.4149 3.3599 17.873
OC 315 CCLE 3.4363 5.2624 2.2086 3.3172
OC 316 CCLE 3.4657 6.1582 1.7902 5.4834
SNU-840 CTRP2 3.5785 11.8245 0.9088 26.0017
ES-2 GDSC1; GDSC2; CCLE 3.7064 5.0876 2.7353 2.2769
TYK-nu GDSC2; CTRP2; CCLE 3.7521 5.4565 3.6753 15.5337
A2780 GDSC2; CTRP2; CCLE 3.8221 7.3558 3.1676 17.2018
OAW28 GDSC2; CTRP2 3.9815 8.8229 2.7058 18.5584
IGROV-1 GDSC2; CTRP2; CCLE 3.997 9.9331 2.2103 20.4103
ONCO-DG-1 CTRP2; CCLE 4.0759 9.3321 2.5679 18.8486
OVCAR-4 GDSC1; GDSC2; CTRP2; CCLE 4.1519 7.2768 3.5484 14.8289
OVKATE GDSC2 4.1643 7.8069 1.7368 7.8113
COV644 CTRP2 4.1899 11.0945 1.8458 21.2711
SNU-8 CTRP2 4.3223 9.9003 2.5438 18.3245
COV318 CCLE 4.3421 5.6834 2.5439 0.5517
COV504 CCLE 4.7452 7.2731 2.0828 1.9597
COV362 CTRP2 4.7473 7.5 4.075 11.1775
OVK18 GDSC2; CTRP2 4.9397 7.5726 4.2384 10.0329
OAW42 GDSC2; CTRP2 5.0073 6.2471 4.8514 7.4642
MCAS CTRP2; CCLE 5.325 9.173 3.8464 10.7246
OVISE GDSC2; CTRP2 5.5251 9.2276 4.0017 9.6422
OVCAR-8 GDSC2; CTRP2; CCLE 5.56 8.9271 4.1818 8.8165
HEY A8 CTRP2; CCLE 6.1101 10.563 3.8396 9.1334
FU-OV-1 GDSC2; CTRP2; CCLE 6.3037 12.0234 3.2682 11.1293
JHOC-5 CTRP2 6.4359 15.3261 1.7257 16.8189
DOV13 GDSC2; CTRP2; CCLE 6.6806 11.4215 3.8659 7.9902
OVSAHO CTRP2; CCLE 7.0162 10.8755 4.383 5.3146
Kuramochi GDSC1; GDSC2; CTRP2; CCLE 7.0904 14.042 2.8804 11.2807
OV56 GDSC2; CTRP2 7.2453 9.3262 5.2633 1.5645
OV-90 GDSC2; CTRP2; CCLE 7.3209 10.7055 4.6725 3.7179
OVTOKO GDSC2; CTRP2; CCLE 7.5196 21.3511 -0.417 21.4921
EFO-27 GDSC2; CTRP2; CCLE 7.5531 18.1832 1.1819 16.6624
TOV-21G GDSC2; CTRP2; CCLE 7.6091 9.1717 5.5131 0.4977
JHOS-2 GDSC2; CTRP2; CCLE 7.7307 13.4445 3.638 7.2581
OV7 CTRP2 7.8027 11.4102 4.6467 3.2227
JHOM-1 CTRP2 7.8677 10.1057 5.2567 1.0476
OVCAR-5 GDSC2; CTRP2 7.9434 18.7867 1.1784 16.0163
SK-OV-3 GDSC2; CTRP2; CCLE 8.1645 20.7573 0.3714 18.1778
ES2 CTRP2 8.1954 13.299 4.0146 5.1542
Caov-3 GDSC2; CTRP2 8.3461 19.2754 1.2353 15.1766
TOV-112D GDSC2; CTRP2; CCLE 8.371 15.5087 3.0827 8.5062
EFO-21 GDSC2; CTRP2; CCLE 9.7054 17.6931 2.9147 7.3991
⏷ Show the Full List of 50 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
P-STS CTRP2 4.5743 9.7492 2.8592 16.475
SYO-1 CTRP2 9.2491 24.4115 -0.6246 19.2494
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 5.12 14.1143 1.2154 21.296
Aska-SS CTRP2 5.1766 8.4116 4.0777 10.1091
TE 617.T CTRP2; CCLE -1.5003 3.6957 -1.6873 50.2425
BT-16 CTRP2 2.6069 4.2142 2.5937 22.9456
GCT GDSC2; CTRP2; CCLE 3.0267 4.1126 3.0245 20.1119
Rh41 GDSC2; CTRP2 3.0272 4.1365 3.0246 20.1095
Hs 633.T GDSC2 3.2339 5.5417 2.1379 7.7557
Rh18 CTRP2 3.2749 4.2019 3.2737 18.4549
TE 441.T GDSC1; GDSC2 3.3187 6.088 1.9363 8.4755
EW-8 GDSC1; GDSC2 3.4458 5.8348 2.1671 6.718
Rh30 GDSC2; CCLE 4.2796 7.2524 2.0862 4.5288
TTC-709 CTRP2 4.3135 7.9022 3.4535 14.7658
STS-0421 GDSC2 4.4187 7.6554 1.987 5.737
SW872 GDSC1; GDSC2 4.7632 7.7953 2.1418 4.0282
SW684 GDSC1; GDSC2 4.7751 5.8966 2.9536 0.2788
A-204 GDSC2; CTRP2; CCLE 4.9116 8.2552 3.8953 11.4864
MFH-ino GDSC1; GDSC2 5.1325 7.7276 2.3822 2.2364
Hs 729.T CTRP2; CCLE 5.2132 8.4628 4.0879 9.9817
G-402 GDSC2; CTRP2; CCLE 5.2218 9.5346 3.5739 12.0795
RD GDSC2; CTRP2; CCLE 5.3184 10.5157 3.1782 13.4888
G-401 GDSC2; CTRP2; CCLE 5.8171 11.3047 3.2225 12.2629
VA-ES-BJ GDSC1; GDSC2 5.9219 7.2795 2.8891 0.0884
Tm87-16 CTRP2 6.1364 11.8378 3.2239 11.6278
SW982 GDSC2; CTRP2 7.0153 10.3391 4.6424 4.2614
RKN GDSC2; CTRP2; CCLE 7.3114 8.7673 5.5379 0.6083
KYM-1 GDSC2; CTRP2; CCLE 7.4035 12.4751 3.8792 6.7756
MES-SA GDSC2; CTRP2; CCLE 7.4508 8.8722 5.5602 0.4642
HT-1080 GDSC2; CTRP2; CCLE 7.5489 11.339 4.5214 4.0128
SK-UT-1 GDSC1; GDSC2; CTRP2 8.4101 13.5065 4.0522 4.7497
SK-LMS-1 GDSC1; GDSC2; CTRP2; CCLE 8.4413 15.1593 3.2964 7.5925
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
IST-Mes2 CCLE 3.0115 4.6464 2.1864 4.3799
NCI-H2452 GDSC2; CTRP2; CCLE 3.7555 6.4256 3.4329 16.3945
MSTO-211H GDSC1; GDSC2; CCLE 4.9361 6.9615 2.6063 1.2329
NCI-H28 GDSC2; CTRP2; CCLE 6.0501 12.3868 2.8779 13.1937
IST-Mes1 GDSC1; GDSC2; CTRP2; CCLE 6.2454 14.2184 2.1236 15.7338
ACC-MESO-1 CTRP2 7.5939 12.1444 4.169 5.3413
JL-1 CTRP2 7.8869 11.8267 4.5064 3.6534
MPP 89 GDSC1; GDSC2; CTRP2; CCLE 8.104 14.1268 3.564 7.0206
NCI-H2052 GDSC2; CTRP2; CCLE 8.163 15.5033 2.943 9.3388
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC1; GDSC2; CTRP2 3.8505 6.8828 3.3783 16.3221
22Rv1 GDSC2; CTRP2; CCLE 4.1274 7.5068 3.4287 15.3586
PC-3 GDSC2; CCLE 4.3216 6.3132 2.5544 2.1714
VCaP GDSC1; GDSC2; CTRP2 4.4522 6.9585 3.9933 12.2887
NCI-H660 GDSC2 4.6961 6.2381 2.7876 0.9297
PaCa-3 CTRP2 8.1019 10.8691 5.0542 1.4961
DU145 GDSC2; CTRP2; CCLE 9.5316 17.8746 2.7215 8.3034
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 1.6478 6.8069 1.0183 31.3586
A-253 GDSC1; GDSC2; CTRP2; CCLE 5.0464 12.8535 1.7761 19.5107
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 2.304 4.1737 1.9015 12.0397
Cancer Drug Sensitivity Data Curated from 46 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-N87 GDSC2; CTRP2; CCLE -4.0074 -0.6273 -4.0119 66.5813
SK-GT-2 GDSC2 -0.9074 3.0427 -1.2205 43.3538
NUGC-4 GDSC2; CTRP2; CCLE -0.6256 4.8363 -0.9441 44.9632
NCC-StC-K140 CTRP2 0.3097 5.1434 0.0069 39.034
SNU-216 CTRP2 0.9139 7.6016 -0.0458 36.8533
AZ-521 CCLE 1.5156 6.449 -0.0769 20.5668
NUGC-3 GDSC2; CTRP2; CCLE 1.6887 8.0096 0.6397 32.363
ECC10 GDSC2 1.9477 3.7663 1.681 15.2358
KE-39 CTRP2; CCLE 2.4764 13.713 -1.0568 34.0783
HSC-39 GDSC1; GDSC2 2.5013 3.4758 2.3801 8.5777
SNU-16 GDSC1; GDSC2; CTRP2; CCLE 2.6399 3.8772 2.6372 22.6902
SNU-620 CTRP2 2.6594 8.3857 1.5245 26.5406
GSS CTRP2 3.0001 4.8393 2.9572 20.4263
HGC-27 GDSC2; CTRP2; CCLE 3.0484 4.2692 3.0433 19.9768
Hs 746.T GDSC2; CTRP2; CCLE 3.232 5.2 3.1576 18.9896
Fu97 GDSC2; CTRP2; CCLE 3.2552 5.0136 3.2075 18.7433
MKN28 GDSC2 3.3452 5.2597 2.3724 5.9442
GCIY GDSC1; GDSC2; CCLE 3.4622 9.0666 0.5656 14.0133
IM95 GDSC2; CTRP2; CCLE 3.5315 10.3304 1.5653 23.9542
SNU-1 GDSC1; GDSC2; CTRP2; CCLE 3.6595 5.9685 3.4621 16.5769
SNU-601 CTRP2 3.6667 5.989 3.4644 16.5465
SCH GDSC1; GDSC2 3.8683 7.1981 1.8182 7.7561
HuG1-N CTRP2 3.9392 8.6595 2.7362 18.5512
MKN74 CTRP2; CCLE 4.0759 7.4393 3.4023 15.6012
BGC-823 CCLE 4.1893 6.8867 1.9358 3.3918
OCUM-1 GDSC2; CTRP2; CCLE 4.2267 6.2426 4.0032 12.8995
RERF-GC-1B GDSC2; CCLE 4.3095 10.7081 0.4161 12.808
TGBC11TKB GDSC2 4.4486 10.603 0.5723 13.8641
SNU-5 GDSC1; GDSC2; CTRP2 4.504 8.3227 2.3062 7.7232
GSU CTRP2 4.5757 5.6691 4.5262 9.9535
SNU-668 CTRP2 4.6868 8.5466 3.5378 13.4819
TMK-1 GDSC2 4.8489 11.716 0.3194 14.2209
RF-48 GDSC1; GDSC2 5.3815 7.3116 2.6719 0.7791
KATO III GDSC2; CTRP2 5.4926 9.0457 4.0623 9.4603
23132/87 GDSC2; CTRP2 5.5594 9.2396 4.0266 9.4647
MKN45 GDSC2; CTRP2; CCLE 6.6121 8.2166 5.3872 1.8398
MKN7 GDSC2; CTRP2; CCLE 6.6921 15.6733 1.7585 16.219
LMSU CTRP2 7.4329 13.1989 3.5479 8.064
MKN1 GDSC2; CTRP2 7.8701 16.4989 2.2496 12.3968
AGS GDSC2; CTRP2 8.2178 13.2401 4.0563 4.9668
SH-10-TC CTRP2; CCLE 8.7338 14.5857 3.7527 5.4886
SNU-719 CTRP2 9.5605 23.1247 0.2275 16.4444
ECC12 GDSC1; GDSC2; CTRP2 10.362 22.2453 1.1979 12.3931
SNU-685 CTRP2 5.2112 7.7765 4.4139 8.6515
SNG-M GDSC2; CTRP2; CCLE 5.7133 10.9462 3.3124 12.1056
SNU-1077 CTRP2 6.2697 11.3219 3.5909 9.8659
⏷ Show the Full List of 46 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KMH-2 GDSC2 3.2037 4.7425 2.5109 5.4892
K5 GDSC1; GDSC2 3.51 5.9625 2.1549 6.6217
TT GDSC2; CTRP2 3.56 6.3422 3.2463 17.6606
SW579 CTRP2; CCLE 3.5642 4.8259 3.5491 16.574
8305C GDSC2; CTRP2; CCLE 3.7897 5.621 3.6851 15.3803
ASH-3 GDSC2 3.8912 5.633 2.5995 3.1596
B-CPAP GDSC2; CTRP2; CCLE 4.0367 5.6046 3.9559 13.6522
IHH-4 GDSC2 4.1733 6.4501 2.3977 3.7897
BHT-101 GDSC2; CTRP2 4.5685 7.3647 3.949 12.1448
WRO GDSC2 4.6194 6.6269 2.5844 1.9849
HTC-C3 GDSC2 4.7506 7.8126 2.1261 4.2831
CGTH-W-1 GDSC1; GDSC2; CTRP2 5.2215 7.7642 4.4297 8.5621
FTC-238 CTRP2 5.2436 7.8579 4.4068 8.6027
TT2609-C02 GDSC2; CTRP2; CCLE 6.5381 10.9361 3.9968 7.6943
ML-1 [Human leukemia] GDSC2; CTRP2 6.6462 8.9312 5.0666 3.0837
CAL-62 GDSC2; CTRP2 7.323 9.6877 5.1457 1.9076
FTC-133 GDSC2; CTRP2 7.5563 10.7859 4.7838 2.993
8505C GDSC2; CTRP2; CCLE 7.7257 12.8678 3.9117 6.1792
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 56 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-10B CTRP2 -1.8483 4.8326 -2.2711 52.1781
BB30-HNC GDSC1; GDSC2 -1.0701 4.2762 -1.762 44.1642
SNU-1076 CTRP2 0.0847 4.4615 -0.1059 40.214
Ca9-22 GDSC2 0.1356 6.7247 -1.44 37.922
SNU-1214 CTRP2 0.1561 4.9597 -0.4692 32.4277
CAL-27 GDSC2; CTRP2; CCLE 0.2415 4.8624 -0.0093 39.3453
JHU-022 GDSC2 0.2732 9.7069 -2.6666 39.9773
JHU-029 GDSC2 0.3397 3.5275 0.009 31.563
SAT [Human HNSCC] GDSC2 0.3617 11.6386 -3.503 40.9495
PCI-15A GDSC2 0.4763 4.0839 -0.0206 31.0232
UPCI-SCC-090 GDSC2 0.628 8.4126 -1.7106 36.3742
DOK GDSC2 0.7354 6.8004 -0.8618 33.2642
CAL-33 GDSC2; CTRP2 0.8777 5.2601 0.599 35.287
FaDu GDSC2; CTRP2; CCLE 1.0556 5.7011 0.6897 34.3851
PE/CA-PJ34 (clone C12) CTRP2 1.2462 9.6033 -0.4608 36.6127
JHU-011 GDSC2 1.2561 8.136 -0.967 31.3996
HO-1-u-1 GDSC2 1.2662 5.9995 0.0359 27.129
KOSC-2 GDSC2 1.3858 6.8859 -0.2508 27.9636
BICR 56 CTRP2 1.4072 10.5343 -0.6854 36.5437
SCC-25 GDSC2; CTRP2; CCLE 1.465 5.0263 1.2834 31.1133
KON GDSC2 1.4703 5.3465 0.534 23.7181
PCI-06A GDSC2 1.5935 9.4484 -1.2788 31.1624
NCI-H3118 GDSC2 1.6307 9.0393 -1.0449 30.202
HO-1-N-1 GDSC2 2.0559 3.8448 1.7691 14.2696
OSC-19 GDSC2 2.1135 9.2368 -0.6944 27.0617
HSC-2 GDSC2; CTRP2; CCLE 2.1751 6.6325 1.6476 27.5934
PE/CA-PJ15 GDSC2; CTRP2 2.181 9.266 0.6583 30.7371
BB49-HNC GDSC1; GDSC2 2.3866 3.9942 2.0627 10.8027
BHY GDSC2; CTRP2 2.5676 9.4418 0.9853 28.577
PCI-04B GDSC2 2.5853 9.9472 -0.6229 25.1293
SAS GDSC2 2.7256 8.362 0.2892 20.3494
PE/CA-PJ49 CTRP2 2.8612 10.0703 1.0101 27.6448
Detroit 562 GDSC2; CTRP2; CCLE 2.9877 8.1982 1.9467 24.1074
BICR 78 GDSC2 3.2177 11.5696 -0.8891 24.2184
HSC-4 GDSC2; CTRP2 3.3205 11.1529 0.974 26.4825
SCC-9 GDSC2; CTRP2; CCLE 3.4591 8.7718 2.1953 21.8833
SCC-15 GDSC1; GDSC2 3.4713 7.8808 1.1658 12.6613
HSC-3 GDSC2; CTRP2 3.4957 8.4371 2.3777 21.1033
SCC-4 GDSC2 3.6766 7.9756 1.2836 11.8102
BICR 22 GDSC2; CTRP2 3.7825 10.1173 1.9128 22.0602
PE/CA-PJ41 (clone D2) CTRP2 4.1092 17.2145 -1.2254 30.3032
SKN-3 GDSC2 4.1669 10.4588 0.4309 15.3384
BICR 10 GDSC2 4.3108 7.5167 1.9805 6.0044
SNU-899 CTRP2 4.4418 6.4083 4.1841 11.5966
BICR 31 GDSC2; CTRP2 4.5182 12.4542 1.4931 21.7271
OSC-20 GDSC2 4.5826 11.0446 0.4542 14.1622
Hs 840.T CCLE 5.1239 8.6845 1.6718 3.3196
PCI-30 GDSC2 5.3353 13.207 -0.0597 14.9705
LB771-HNC GDSC1; GDSC2 5.6604 14.5406 -0.4782 15.7573
YD-8 CTRP2 5.7274 15.5019 1.049 20.5472
BICR 18 CTRP2 6.3447 13.3378 2.6448 13.5483
SNU-46 CTRP2 6.3779 10.1678 4.2536 6.9063
SNU-1041 CTRP2 7.07 18.6348 0.5822 19.4274
BICR 6 CTRP2 7.3442 15.2104 2.4944 12.3441
BICR 16 CTRP2 8.2752 19.5023 1.072 15.8231
SNU-1066 CTRP2 8.7078 16.5365 2.8176 9.0362
⏷ Show the Full List of 56 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-BLC1 CTRP2 -1.4224 2.3034 -1.4634 49.7511
SCaBER CTRP2; CCLE 0.4847 5.8126 0.0386 38.2692
5637 GDSC2; CTRP2; CCLE 1.3441 5.6793 1.0098 32.4043
KMBC-2 CTRP2; CCLE 3.0751 11.1513 0.732 27.902
CAL-29 GDSC2; CTRP2 3.1804 9.1969 1.7231 24.3583
BFTC-905 GDSC2 3.3991 5.6566 2.2183 6.766
RT-112 GDSC2; CTRP2; CCLE 3.9997 5.3506 3.957 13.7667
VM-CUB-1 CTRP2 4.5931 12.5449 1.5175 21.4653
TCCSUP GDSC2; CTRP2; CCLE 4.7227 8.719 3.4922 13.5782
647V GDSC2; CTRP2 4.7308 7.8879 3.8849 11.9775
SW780 GDSC2; CCLE 4.8136 10.4553 0.9089 9.4203
JMSU-1 CTRP2; CCLE 4.8515 6.9443 4.4209 9.5424
HT-1376 GDSC2; CTRP2; CCLE 5.311 12.9181 1.9787 18.1895
SW1710 GDSC2; CTRP2 5.3328 9.1715 3.8543 10.6747
253J-BV CTRP2 5.3484 9.3576 3.7772 10.9593
UM-UC-1 CTRP2 5.4891 9.5457 3.8119 10.509
RT-4 GDSC2; CTRP2; CCLE 5.6421 13.881 1.786 18.1888
639V GDSC2; CTRP2; CCLE 7.2504 8.868 5.4658 0.871
J82 GDSC2; CTRP2; CCLE 7.3848 14.2474 2.9993 10.323
UM-UC-3 GDSC2; CTRP2; CCLE 7.8149 11.0232 4.8298 2.533
KU-19-19 GDSC2; CTRP2 7.8735 9.0625 5.6602 0.1207
HT-1197 GDSC2; CTRP2; CCLE 7.9468 13.0815 3.9569 5.6989
BC-3C CTRP2 8.001 15.2987 2.929 9.6327
T24 GDSC2; CTRP2; CCLE 8.3963 13.3943 4.0955 4.6031
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DSH1 GDSC1; GDSC2 -2.4831 4.0635 -3.2303 54.3555
CAL-39 GDSC2 -1.1463 2.6612 -1.3911 45.3969
OVCA420 GDSC2 -0.2805 7.103 -2.0331 41.3491
BPH-1 GDSC2 0.0969 10.5199 -3.2228 41.5788
OVMIU GDSC2 0.9519 9.7795 -2.0456 35.8963
PA-1 GDSC2 2.0837 3.2209 1.9968 12.8805
OVCA433 GDSC2 2.1179 6.5035 0.6427 20.5751
OV17R GDSC2 2.2308 4.0124 1.8909 12.8325
JAR GDSC1; GDSC2 2.4167 3.3963 2.3128 9.3023
NT2-D1 GDSC1; GDSC2 2.6623 8.0304 0.3976 19.3675
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 2.721 5.1591 1.8646 10.7497
Ca Ski GDSC2 2.9335 8.3372 0.4836 18.6353
SW954 GDSC1; GDSC2 2.9361 10.3462 -0.5167 22.8969
TC-YIK GDSC2 2.9509 7.5514 0.8906 16.2937
DoTc2 4510 GDSC2 3.0784 6.9904 1.2809 13.5726
UWB1.289 GDSC2 3.1737 8.2611 0.7277 16.5285
MS751 GDSC2 3.4179 8.3223 0.9013 14.8037
C-33 A GDSC2 3.7014 10.6648 -0.0383 19.0041
ME-180 GDSC2 3.7093 17.1165 -3.2553 30.2243
C-4-I GDSC2 3.7154 9.8773 0.3661 16.9101
KGN GDSC1; GDSC2 3.8564 6.8164 1.9976 6.7088
SKN GDSC2 3.9199 6.9255 1.991 6.8336
ACC-OV7 GDSC2 4.0441 11.9279 -0.3951 19.7302
JHOS-3 GDSC2 4.1872 9.6358 0.8539 12.9701
JEG-3 GDSC2 4.2115 8.5305 1.4167 9.6312
HEY GDSC2 4.2543 6.6198 2.3702 3.7925
LB831-BLC GDSC1; GDSC2 4.2871 6.4629 2.4644 3.0713
NCC-IT GDSC1; GDSC2 4.4927 6.4149 2.6078 1.974
PEO1 GDSC2 4.5763 11.0647 0.4397 14.2542
NEC8 GDSC1; GDSC2 4.5935 6.9615 2.4209 2.7977
PWR-1E GDSC2 4.6096 6.7339 2.5319 2.2729
SiHa GDSC2 5.0199 6.7348 2.7378 0.8425
HEC-1 GDSC2 5.287 6.6431 2.8814 0.2515
SKG-IIIa GDSC2 5.4013 12.5587 0.3007 13.062
SW962 GDSC1; GDSC2 5.5613 16.1424 -1.3313 19.4252
SW756 GDSC2 5.7763 7.942 2.5987 0.7877
SiSo GDSC2 5.8091 7.6036 2.7366 0.3809
HT-3 GDSC2 6.031 9.432 2.1201 2.4837
HeLa GDSC2; CTRP2 7.4565 8.297 5.7745 0.0627
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lapatinib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Eribulin. Breast cancer [2C60-2C6Y] [20]
Talazoparib DM1KS78 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [21]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Lapatinib caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [22]
LY2835219 DM93VBZ Moderate Decreased metabolism of Lapatinib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [23]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Lapatinib caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Tucatinib DMBESUA Major Decreased metabolism of Lapatinib caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [25]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Lapatinib caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [24]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Lapatinib caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
⏷ Show the Full List of 8 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Lapatinib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [25]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Lapatinib and Ivosidenib. Acute myeloid leukaemia [2A60] [27]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Arn-509. Acute myeloid leukaemia [2A60] [25]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [21]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Oliceridine. Acute pain [MG31] [20]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Ivabradine. Angina pectoris [BA40] [21]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Lapatinib and Dronedarone. Angina pectoris [BA40] [20]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Lapatinib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [28]
Posaconazole DMUL5EW Major Decreased metabolism of Lapatinib caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [25]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Levalbuterol. Asthma [CA23] [29]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Pirbuterol. Asthma [CA23] [30]
Troleandomycin DMUZNIG Major Decreased metabolism of Lapatinib caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [25]
Ag-221 DMS0ZBI Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [25]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Retigabine. Behcet disease [4A62] [20]
Cariprazine DMJYDVK Moderate Decreased metabolism of Lapatinib caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [21]
Erdafitinib DMI782S Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [31]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Lapatinib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [32]
Macitentan DMP79A1 Moderate Decreased metabolism of Lapatinib caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [33]
PF-04449913 DMSB068 Moderate Decreased metabolism of Lapatinib caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [34]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [30]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [29]
Revefenacin DMMP5SI Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [35]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Indacaterol. Chronic obstructive pulmonary disease [CA22] [30]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Arformoterol. Chronic obstructive pulmonary disease [CA22] [30]
Dihydrocodeine DMB0FWL Moderate Decreased metabolism of Lapatinib caused by Dihydrocodeine mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [36]
Fidaxomicin DMFP6MV Minor Decreased clearance of Lapatinib due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [25]
Intedanib DMSTA36 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Intedanib. Colorectal cancer [2B91] [37]
Drospirenone DM1A9W3 Moderate Decreased metabolism of Lapatinib caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [24]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Lapatinib caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [24]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Probucol. Coronary atherosclerosis [BA80] [20]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Lapatinib and Pasireotide. Cushing syndrome [5A70] [20]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Osilodrostat. Cushing syndrome [5A70] [21]
Ivacaftor DMZC1HS Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [38]
MK-8228 DMOB58Q Moderate Decreased metabolism of Lapatinib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [24]
Rivaroxaban DMQMBZ1 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [39]
Polatuzumab vedotin DMF6Y0L Moderate Decreased metabolism of Lapatinib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [40]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Lapatinib caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [36]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [20]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Lapatinib and Deutetrabenazine. Dystonic disorder [8A02] [41]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Ingrezza. Dystonic disorder [8A02] [42]
Cenobamate DM8KLU9 Moderate Increased metabolism of Lapatinib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Stiripentol DMMSDOY Moderate Decreased metabolism of Lapatinib caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [21]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Lapatinib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [25]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Cannabidiol. Epileptic encephalopathy [8A62] [21]
Bay 80-6946 DMLOS5R Moderate Decreased metabolism of Lapatinib caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [43]
Tazemetostat DMWP1BH Moderate Increased metabolism of Lapatinib caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [25]
Solifenacin DMG592Q Moderate Decreased metabolism of Lapatinib caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [44]
Mirabegron DMS1GYT Minor Decreased metabolism of Lapatinib caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [45]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Lapatinib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [21]
Ripretinib DM958QB Moderate Decreased metabolism of Lapatinib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [25]
Sunitinib DMCBJSR Moderate Decreased metabolism of Lapatinib caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [24]
Avapritinib DMK2GZX Moderate Decreased metabolism of Lapatinib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [21]
Digitoxin DMWVIGP Moderate Decreased metabolism of Lapatinib caused by Digitoxin mediated inhibition of CYP450 enzyme. Heart failure [BD10-BD1Z] [24]
Boceprevir DMBSHMF Major Decreased metabolism of Lapatinib caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [24]
Telaprevir DMMRV29 Major Decreased metabolism of Lapatinib caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [25]
GS-5885 DMSL3DX Moderate Decreased clearance of Lapatinib due to the transporter inhibition by GS-5885. Hepatitis virus infection [1E50-1E51] [46]
GS-9857 DMYU6P5 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [47]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [48]
MK-1439 DM215WE Minor Decreased metabolism of Lapatinib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [49]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Lapatinib caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [50]
Cobicistat DM6L4H2 Major Decreased metabolism of Lapatinib caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Etravirine DMGV8QU Moderate Increased metabolism of Lapatinib caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [25]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [20]
Darunavir DMN3GCH Moderate Decreased metabolism of Lapatinib caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [24]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Lapatinib and Mipomersen. Hyper-lipoproteinaemia [5C80] [51]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Lapatinib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [20]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Lapatinib and BMS-201038. Hyper-lipoproteinaemia [5C80] [52]
Aliskiren DM1BV7W Moderate Decreased metabolism of Lapatinib caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [20]
Levamlodipine DM92S6N Moderate Decreased metabolism of Lapatinib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [24]
Tolvaptan DMIWFRL Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [53]
Berotralstat DMWA2DZ Major Decreased clearance of Lapatinib due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [54]
Suvorexant DM0E6S3 Moderate Decreased metabolism of Lapatinib caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
Amobarbital DM0GQ8N Moderate Increased metabolism of Lapatinib caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [25]
ITI-007 DMUQ1DO Moderate Decreased metabolism of Lapatinib caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [55]
Quazepam DMY4D87 Moderate Decreased metabolism of Lapatinib caused by Quazepam mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [24]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Polyethylene glycol. Irritable bowel syndrome [DD91] [21]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Lapatinib and Phenolphthalein. Irritable bowel syndrome [DD91] [20]
Eluxadoline DMYZ0P1 Major Decreased clearance of Lapatinib due to the transporter inhibition by Eluxadoline. Irritable bowel syndrome [DD91] [21]
Naloxegol DML0B41 Minor Decreased metabolism of Lapatinib caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [56]
Pemigatinib DM819JF Moderate Decreased metabolism of Lapatinib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [21]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Lapatinib and Crizotinib. Lung cancer [2C25] [57]
Brigatinib DM7W94S Moderate Decreased metabolism of Lapatinib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [25]
Ceritinib DMB920Z Major Decreased metabolism of Lapatinib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [25]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Lapatinib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [58]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Lapatinib and Osimertinib. Lung cancer [2C25] [59]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Lapatinib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [60]
Capmatinib DMYCXKL Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [61]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Lapatinib and Selpercatinib. Lung cancer [2C25] [21]
Artesunate DMR27C8 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Artesunate. Malaria [1F40-1F45] [24]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Lapatinib and Hydroxychloroquine. Malaria [1F40-1F45] [62]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [21]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Lapatinib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [63]
Idelalisib DM602WT Major Decreased metabolism of Lapatinib caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [25]
GDC-0199 DMH0QKA Major Decreased clearance of Lapatinib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [25]
IPI-145 DMWA24P Moderate Decreased metabolism of Lapatinib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [24]
Acalabrutinib DM7GCVW Moderate Decreased metabolism of Lapatinib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [64]
Ibrutinib DMHZCPO Moderate Decreased metabolism of Lapatinib caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [65]
Arry-162 DM1P6FR Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Arry-162. Melanoma [2C30] [25]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Lapatinib and Vemurafenib. Melanoma [2C30] [20]
Selumetinib DMC7W6R Moderate Decreased metabolism of Lapatinib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [66]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and LGX818. Melanoma [2C30] [67]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Lapatinib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [25]
Danazol DML8KTN Moderate Decreased metabolism of Lapatinib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [24]
Ubrogepant DM749I3 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Ubrogepant. Migraine [8A80] [68]
Rimegepant DMHOAUG Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Rimegepant. Migraine [8A80] [69]
Lasmiditan DMXLVDT Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [70]
Exjade DMHPRWG Moderate Decreased metabolism of Lapatinib caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [71]
Flibanserin DM70DTN Moderate Decreased metabolism of Lapatinib caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [72]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Lapatinib and Panobinostat. Multiple myeloma [2A83] [73]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Siponimod. Multiple sclerosis [8A40] [25]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Fingolimod. Multiple sclerosis [8A40] [20]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Lapatinib and Ozanimod. Multiple sclerosis [8A40] [74]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Romidepsin. Mycosis fungoides [2B01] [20]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Lapatinib and Nilotinib. Myeloproliferative neoplasm [2A20] [20]
Ruxolitinib DM7Q98D Minor Decreased metabolism of Lapatinib caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [21]
Rolapitant DM8XP26 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [75]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Entrectinib. Non-small cell lung cancer [2C25] [25]
S-297995 DM26IH8 Moderate Decreased clearance of Lapatinib due to the transporter inhibition by S-297995. Opioid use disorder [6C43] [21]
Olaparib DM8QB1D Moderate Decreased metabolism of Lapatinib caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [76]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Rucaparib. Ovarian cancer [2C73] [20]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Triclabendazole. Parasitic worm infestation [1F90] [20]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Pimavanserin. Parkinsonism [8A00] [77]
Abametapir DM2RX0I Moderate Decreased metabolism of Lapatinib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [78]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Lapatinib and Macimorelin. Pituitary gland disorder [5A60-5A61] [79]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Lapatinib and Lefamulin. Pneumonia [CA40] [80]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Lapatinib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [25]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Degarelix. Prostate cancer [2C82] [21]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Lapatinib and ABIRATERONE. Prostate cancer [2C82] [21]
Enzalutamide DMGL19D Moderate Decreased metabolism of Lapatinib caused by Enzalutamide mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [25]
Relugolix DMK7IWL Major Decreased clearance of Lapatinib due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [81]
Darolutamide DMV7YFT Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [82]
Silodosin DMJSBT6 Moderate Decreased metabolism of Lapatinib caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [83]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Levomepromazine. Psychotic disorder [6A20-6A25] [20]
Selexipag DMAHSU0 Moderate Decreased metabolism of Lapatinib caused by Selexipag mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [84]
Riociguat DMXBLMP Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [25]
Everolimus DM8X2EH Moderate Decreased metabolism of Lapatinib caused by Everolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [85]
Axitinib DMGVH6N Moderate Decreased metabolism of Lapatinib caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [21]
Temsirolimus DMS104F Moderate Decreased metabolism of Lapatinib caused by Temsirolimus mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [86]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Lapatinib and Iloperidone. Schizophrenia [6A20] [20]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Paliperidone. Schizophrenia [6A20] [20]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Lapatinib and Amisulpride. Schizophrenia [6A20] [87]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Asenapine. Schizophrenia [6A20] [20]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Lapatinib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [24]
Tedizolid DMG2SKR Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Tedizolid. Skin and skin-structure infection [1F28-1G0Z] [21]
LDE225 DMM9F25 Moderate Decreased metabolism of Lapatinib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [88]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Lapatinib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [21]
Larotrectinib DM26CQR Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [25]
Trabectedin DMG3Y89 Moderate Decreased metabolism of Lapatinib caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [21]
Armodafinil DMGB035 Moderate Decreased metabolism of Lapatinib caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [24]
LEE011 DMMX75K Major Decreased metabolism of Lapatinib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [20]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Lapatinib and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [20]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [21]
Pitolisant DM8RFNJ Moderate Increased metabolism of Lapatinib caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [21]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [20]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Lapatinib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [89]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [90]
Eltrombopag DMOGFIX Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [91]
Apixaban DM89JLN Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [21]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Lapatinib and Lenvatinib. Thyroid cancer [2D10] [20]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Lapatinib and Cabozantinib. Thyroid cancer [2D10] [21]
Saxagliptin DMGXENV Moderate Decreased metabolism of Lapatinib caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [21]
Elagolix DMB2C0E Moderate Increased metabolism of Lapatinib caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [25]
Fluticasone DMGCSVF Moderate Decreased clearance of Lapatinib due to the transporter inhibition by Fluticasone. Vasomotor/allergic rhinitis [CA08] [24]
⏷ Show the Full List of 164 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sunset yellow FCF E00255 17730 Colorant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Certolake sunset yellow E00351 61817 Colorant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lapatinib 250 mg tablet 250 mg Oral Tablet Oral
Lapatinib Ditosylate eq 250mg base tablet eq 250mg base Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5692).
2 Lapatinib FDA Label
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011 Feb 20;29(6):667-73. doi: 10.1200/JCO.2010.31.3197. Epub 2011 Jan 18.
7 Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
8 Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.BMC Cancer. 2016 Oct 19;16(1):813.
9 The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos. 2008 Apr;36(4):695-701.
10 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
11 Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol. 2010 Oct;78(4):693-703.
12 Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
13 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
14 Effects of lapatinib on cell proliferation and apoptosis in NB4 cells. Oncol Lett. 2018 Jan;15(1):235-242. doi: 10.3892/ol.2017.7342. Epub 2017 Nov 3.
15 Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
16 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
17 The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib. Toxicol Sci. 2023 Dec 21;197(1):69-78. doi: 10.1093/toxsci/kfad099.
18 CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul;5(7-8):261-72. doi: 10.18632/genesandcancer.24.
19 The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 2005 Jan 1;65(1):18-25.
20 Canadian Pharmacists Association.
21 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
23 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
24 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
25 Cerner Multum, Inc. "Australian Product Information.".
26 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
27 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
28 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
29 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
30 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
31 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
32 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
33 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
34 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
35 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
36 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
37 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
38 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
39 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
40 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
41 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
42 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
43 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
44 Product Information. VESIcare (solifenacin). GlaxoSmithKline, Research Triangle Park, NC.
45 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
46 Product Information. Harvoni (ledipasvir-sofosbuvir). Gilead Sciences, Foster City, CA.
47 Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). Gilead Sciences, Foster City, CA.
48 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
49 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
50 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
51 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
52 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
53 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
54 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
55 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
56 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
57 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
58 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
59 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
60 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
61 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
62 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
63 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
64 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65 Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
66 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
67 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
68 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
69 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
70 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
71 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
72 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
73 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
74 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
75 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
76 Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
77 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
78 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
79 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
80 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
81 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
82 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
83 Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
84 Product Information. Uptravi (selexipag). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
85 Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
86 Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
87 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
88 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
89 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
90 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
91 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]